Respiratory system disorder
MONDO:0005087A non-neoplastic or neoplastic disorder that affects the respiratory system. Representative examples include pneumonia, chronic obstructive pulmonary disease, pulmonary failure, lung adenoma, lung carcinoma, and tracheal carcinoma.
Also known as: disease of respiratory system, disease or disorder of respiratory system, disorder of respiratory system, respiratory disease, respiratory disorder, respiratory system disease, respiratory system disease or disorder, respiratory system disorder
9451 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 3592 trials in this tab.
-
New universal flu vaccine enters human testing
⭐️ VACCINE ⭐️ Recruiting nowThis study tests an experimental flu vaccine called BPL-1357, given as a shot or nasal spray, to see if it is safe and can protect against multiple flu types. About 129 healthy adults aged 18-55 will receive the vaccine or a placebo, then be exposed to a flu virus in a controlled…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 03, 2026 23:00 UTC
-
One shot for two viruses? new combo vaccine enters early human testing
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage study is testing a new mRNA vaccine that aims to protect against both seasonal flu and COVID-19 with a single shot. Around 1,475 healthy adults aged 65 to 85 will receive either the new combo vaccine, a standard flu vaccine, or a licensed COVID-19 vaccine. Resear…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 02, 2026 00:00 UTC
-
Custom-Made cancer vaccine targets leftover disease after surgery
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage trial tests a personalized cancer vaccine for people with bladder or stomach cancer who still have tiny amounts of cancer DNA in their blood after surgery. The vaccine is made from unique proteins in each person's tumor and aims to train the immune system to find…
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:00 UTC
-
Can a COPD inhaler also help your heart?
Disease control Recruiting nowThis study tests a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) against a placebo in 56 people with COPD and lung hyperinflation. The goal is to see if the inhaler improves both lung function and heart function, measured by MRI. Participants will receiv…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New trial aims to find best treatment for older lung cancer patients
Disease control Recruiting nowThis phase III trial compares adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in adults aged 70+ with advanced non-small cell lung cancer. The goal is to see if the combination improves survival. About 304 participants will be enrolled.
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New combo aims to outperform chemo for tough lung cancer
Disease control Recruiting nowThis study tests a new combination of two drugs (trastuzumab deruxtecan and pembrolizumab) against standard chemotherapy plus pembrolizumab as a first treatment for people with advanced non-small cell lung cancer that has high levels of HER2 and low PD-L1. About 686 adults will t…
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Engineered immune cells take on metastatic tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Targeted radiation after lung cancer surgery aims to stop return
Disease control Recruiting nowThis study tests whether adding a precise type of radiation therapy (I²-PORT) after lung cancer surgery can help prevent the cancer from coming back. Participants have non-small cell lung cancer with remaining cancer in lymph nodes after initial treatment. The trial compares stan…
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New radiation approach aims to spare healthy tissue in sinus cancer treatment
Disease control Recruiting nowThis Phase 2 trial tests a new way to give radiation for sinus cancer after endoscopic surgery. Instead of radiating the whole sinus area, doctors will use a 'dose painting' technique that targets only the areas where cancer was found. The goal is to see if this reduces side effe…
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New inhaled drug for lung scarring moves to Long-Term safety check
Disease control Recruiting nowThis study looks at the long-term safety of an inhaled drug (AP01) for people with progressive lung scarring (pulmonary fibrosis). It is for those who already completed an earlier Avalyn Pharma study. About 340 participants will receive the drug and be monitored for side effects …
Phase: PHASE2 • Sponsor: Avalyn Pharma Inc. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug EVOLVE104 takes on tough cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…
Phase: PHASE1 • Sponsor: EvolveImmune United, Inc • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Could adding radiation to immunotherapy keep lung cancer at bay?
Disease control Recruiting nowThis study tests whether adding radiation therapy to the usual maintenance drug atezolizumab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 138 participants who have already responded to initial chemo-immunotherapy will be…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called BMS-986490, alone or with bevacizumab, in people with advanced solid tumors that have a specific marker (CEACAM5). The goal is to see if the treatment is safe and works against these cancers. About 360 participants will take part in this early-s…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New combo therapy aims to keep lung cancer from returning after surgery
Disease control Recruiting nowThis phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy after surgery can help prevent non-small cell lung cancer from coming back. About 1,210 people with stage II to IIIB lung cancer will receive either chemo plus pembrolizumab toge…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New inhaled drug aims to fight deadly lung scarring
Disease control Recruiting nowThis Phase 2 trial tests an experimental inhaled medication called LTI-03 in about 120 people with idiopathic pulmonary fibrosis (IPF), a progressive lung disease that causes scarring and breathing difficulty. Participants will inhale LTI-03 or a placebo twice daily for 24 weeks.…
Phase: PHASE2 • Sponsor: Rein Therapeutics • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Which antibiotic works best for pneumonia? new study aims to find out
Disease control Recruiting nowThis study compares two common antibiotics, azithromycin and doxycycline, in adults hospitalized with community-acquired pneumonia who are also receiving a beta-lactam antibiotic. The goal is to see which combination helps patients leave the hospital sooner and reduces the need f…
Phase: PHASE4 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New Antibody-Drug conjugate takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called ALE.P03 in adults with advanced or metastatic solid tumors that have a specific protein (Claudin-1) on their surface. The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial has two phases: …
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
App aims to put asthma control in Teens' pockets
Disease control Recruiting nowThis study tests a smartphone app called SMART@Home designed to help teenagers with asthma manage their condition. The app sends daily reminders for medication and diary entries, provides educational content, and connects to Bluetooth devices like a spirometer to track lung funct…
Phase: NA • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
COPD drug astegolimab tested for Long-Term safety in 2,000 patients
Disease control Recruiting nowThis study looks at the long-term safety of the drug astegolimab in people with chronic obstructive pulmonary disease (COPD). It includes about 2,000 participants who already completed a one-year study with the drug. The main goal is to track any side effects that may occur with …
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New asthma drug aims to clear mucus and protect airways
Disease control Recruiting nowThis study tests a drug called depemokimab in 150 adults with severe asthma caused by a specific type of inflammation. The goal is to see if the drug can reduce mucus plugs and airway thickening in the lungs. Participants will receive the drug and have lung scans and breathing te…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Sound waves vs. superbugs: can a simple ultrasound curb unnecessary antibiotics in kids?
Disease control Recruiting nowThis study investigates whether using lung ultrasound (a safe, radiation-free imaging technique) can help doctors decide when to stop antibiotics in children and teens hospitalized with lower respiratory tract infections like pneumonia. Half of the participants will receive a lun…
Phase: NA • Sponsor: American University of Beirut Medical Center • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Inhaled drug combo aims to boost lung cancer treatment before surgery
Disease control Recruiting nowThis study tests whether adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy (durvalumab) can improve outcomes for people with early-stage non-small cell lung cancer before they have surgery. The trial involves 60 adults with operable stage I…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New enzyme pill could help cystic fibrosis patients digest food better
Disease control Recruiting nowThis study tests a new medicine called ANG003 for people with cystic fibrosis who have trouble digesting food (exocrine pancreatic insufficiency). The medicine is a type of enzyme replacement therapy, similar to the current standard treatment Creon. About 113 participants will re…
Phase: PHASE2 • Sponsor: Anagram Therapeutics, Inc. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug combo aims to reduce surgeries for rare HPV throat condition
Disease control Recruiting nowThis early-phase study tests two cancer drugs—lenvatinib (a daily pill) and pembrolizumab (an IV infusion)—in 20 adults with HPV-related recurrent respiratory papillomatosis (RRP) that has spread to the lungs. The goal is to see if the combination can shrink papillomas and reduce…
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug AWT020 takes on advanced solid tumors
Disease control Recruiting nowThis phase 1 trial tests a new drug called AWT020, given alone or with other cancer treatments, in people with advanced solid tumors such as non-small cell lung cancer, colorectal cancer, kidney cancer, and melanoma. The main goals are to check the drug's safety, find the best do…
Phase: PHASE1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug combo takes on tough cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called BMS-986488, alone or combined with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 437 adults w…
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug combo aims to fight aggressive lung cancer
Disease control Recruiting nowThis study tests a new drug called ABBV-706 combined with the immunotherapy atezolizumab as a first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. About 180 adults will receive either the new combination at one of two dose…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Could immunotherapy replace Chemo-Radiation after head and neck cancer surgery?
Disease control Recruiting nowThis phase II trial is testing whether the immunotherapy drug pembrolizumab (Keytruda) alone can work better than the usual combination of chemotherapy and radiation after surgery for head and neck cancer that has come back or is a new primary tumor. About 188 adults aged 18-79 w…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New combo therapy aims to stop head and neck cancer from returning
Disease control Recruiting nowThis phase II trial is testing whether adding chemotherapy or chemo-immunotherapy before standard salvage surgery can improve outcomes for patients with PD-L1 positive head and neck cancer that has come back. About 180 participants will receive either carboplatin and paclitaxel, …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New antibody aims to cut lung attacks in bronchiectasis patients
Disease control Recruiting nowThis study tests an experimental drug called AZD0292 in 435 people aged 12 and older who have bronchiectasis and a long-term lung infection with Pseudomonas aeruginosa. The goal is to see if the drug can reduce the number of moderate-to-severe lung flare-ups compared to a placebo…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Could an immune booster keep early lung cancer from returning?
Disease control Recruiting nowThis phase 3 trial is testing whether the immunotherapy drug durvalumab, given after surgery, can prevent early-stage non-small cell lung cancer from coming back. About 306 participants who have had their tumor completely removed will be randomly assigned to receive durvalumab or…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New combo aims to outsmart lung Cancer's growth signals
Disease control Recruiting nowThis Phase III trial is testing whether adding bevacizumab to the standard drug osimertinib can better control advanced EGFR-mutant non-small cell lung cancer. About 300 people with stage IIIB or IV disease will be randomly assigned to receive either the combination or osimertini…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug infusion targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or certain other solid tumors. The drug is given as an infusion every 3 weeks. The study has two parts: Part 1 finds the best dose in stomach/GEJ cancer patients, an…
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Lung cancer trial tests whether chemo before surgery boosts survival
Disease control Recruiting nowThis phase III trial is testing whether giving chemotherapy and immunotherapy both before and after surgery (perioperative) is better than giving it only after surgery (adjuvant) for people with stage II-IIIB non-small cell lung cancer that can be removed. About 1,100 participant…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Could vitamin B3 help beat TB? new trial launches
Disease control Recruiting nowThis phase 2 trial tests whether adding nicotinamide (a form of vitamin B3) to a standard three-drug regimen can safely and effectively treat drug-susceptible pulmonary tuberculosis. About 165 adults with newly diagnosed TB will receive one of two doses of nicotinamide plus the s…
Phase: PHASE2 • Sponsor: Gates Medical Research Institute • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Could immunotherapy boost radiation for head and neck cancer?
Disease control Recruiting nowThis study compares standard radiation plus cisplatin against two experimental approaches: radiation with docetaxel and cetuximab, or radiation with cisplatin and the immunotherapy drug atezolizumab. About 613 patients with high-risk stage III-IV head and neck cancer will partici…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug aims to cut dangerous lung Flare-Ups in chronic disease
Disease control Recruiting nowThis study tests a new drug called GSK3862995B in 446 adults with bronchiectasis, a long-term lung condition. The goal is to see if the drug can reduce the number of serious lung infections (exacerbations) compared to a placebo. Participants will receive either one of two doses o…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Texts vs. manuals: new trial aims to help rural cancer survivors kick the habit
Disease control Recruiting nowThis study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New hope for rare lung cancer: targeted drug trial launches
Disease control Recruiting nowThis study tests a new drug, firmonertinib, against two standard treatments for people with advanced non-small-cell lung cancer that has certain rare genetic changes (EGFR PACC mutations). About 480 participants who have not had prior treatment for advanced disease will be random…
Phase: PHASE3 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Immunotherapy combo before surgery shows promise for tough mesothelioma
Disease control Recruiting nowThis phase II trial is testing whether giving two immunotherapy drugs, nivolumab and ipilimumab, before surgery can help control sarcomatoid mesothelioma, a rare and aggressive cancer of the lung lining. The study will enroll 26 people with stage I to IIIa disease. The main goals…
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New combo therapy aims to extend life in advanced lung cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding the experimental drug MK-2870 to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer live longer compared to pembrolizumab alone. The study enrolls about 614 adults whose tumors have high PD-L1 lev…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New pill combo takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New device aims to wean ventilator patients faster
Disease control Recruiting nowThis study tests a temporary device that stimulates the diaphragm (the main breathing muscle) in ICU patients on breathing machines. The goal is to see if it helps patients breathe more on their own and recover from lung injury. About 30 adults with severe breathing failure will …
Phase: NA • Sponsor: Lungpacer Medical Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New trial tests smarter radiation to protect memory in lung cancer patients
Disease control Recruiting nowThis phase III trial is testing whether a precise, high-dose radiation technique called stereotactic radiosurgery (SRS) is better at preserving memory and thinking than the current standard of whole brain radiation that avoids the hippocampus (the brain's memory center) plus a dr…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New immune cell therapy targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could an immunotherapy drug keep early lung cancer from returning?
Disease control Recruiting nowThis phase III trial is testing whether the immunotherapy drug atezolizumab, given after surgery, can prevent stage I non-small cell lung cancer from returning. About 336 patients who have had their tumor completely removed will be randomly assigned to receive either atezolizumab…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill combo aims to protect vulnerable from severe COVID
Disease control Recruiting nowThis phase 3 trial tests a new antiviral pill, ibuzatrelvir, alone or with an IV drug (remdesivir) in 300 adults with weak immune systems who have mild-to-moderate COVID-19. The goal is to see if the combination prevents hospitalizations or worsening symptoms better than remdesiv…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Saline wash may offer safer way to treat lung infections
Disease control Recruiting nowThis phase 3 trial tests whether early irrigation of the chest cavity with saline can improve outcomes for people with complicated pleural infections. 244 adults will receive either standard care or saline irrigation twice daily for three days. The goal is to see if this approach…
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug cocktail aims to stop lung cancer in its tracks
Disease control Recruiting nowThis study tests whether adding two immunotherapy drugs (tislelizumab and surufatinib) to standard chemoradiation can help people with stage III non-small cell lung cancer that cannot be surgically removed. About 160 participants will be randomly assigned to receive either the tw…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New antibody combo aims to boost lung cancer treatment response
Disease control Recruiting nowThis study tests whether adding the experimental drug visugromab to standard chemotherapy and immunotherapy can shrink tumors better than standard treatment alone in people with advanced non-squamous lung cancer that has not been treated before. About 107 adults with newly diagno…
Phase: PHASE2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
AI-Powered ventilator coach aims to protect lungs in ICU
Disease control Recruiting nowThis trial tests a real-time algorithm-driven system that gives doctors feedback on ventilator settings to protect the lungs of critically ill patients. The study will include 208 adults on breathing machines with acute respiratory distress syndrome (ARDS). The goal is to see if …
Phase: NA • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for aggressive lung cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests whether a new drug called BNT327, combined with standard chemotherapy, helps people with advanced small-cell lung cancer live longer compared to another approved drug (atezolizumab) plus the same chemo. About 621 adults who have not yet been treated for their can…
Phase: PHASE3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for lung cancer patients: targeted drug Dato-DXd faces off against chemo
Disease control Recruiting nowThis phase 3 trial compares a new targeted drug, datopotamab deruxtecan (Dato-DXd), against the standard chemotherapy docetaxel in 400 people with advanced or metastatic non-squamous non-small cell lung cancer that lacks certain gene mutations. The goal is to see if Dato-DXd can …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: experimental drug enters human testing
Disease control Recruiting nowThis early-phase study tests an experimental drug called mevrometostat in adults with certain advanced cancers that have stopped responding to standard treatments. The study is currently enrolling men with castration-resistant prostate cancer. Participants receive the drug by mou…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called BMS-986507, alone or with other cancer medicines, in adults with advanced lung or breast cancer that has spread. The goal is to check safety, side effects, and how well the drugs work. About 416 participants will receive different combinations t…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill shows promise for Hard-to-Treat cancers with BRAF mutation
Disease control Recruiting nowThis early-stage trial is testing a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors that have a specific BRAF gene change. The drug is given alone or combined with other medicines like binimetinib or cetuximab. The study aims to find safe doses …
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Inhaled interferon could be new weapon against severe RSV in young children
Disease control Recruiting nowThis phase 3 trial tests whether an inhaled solution of human interferon α1b can safely help children under 2 years old recover from respiratory syncytial virus (RSV) lower respiratory tract infections. The study compares the interferon treatment to a placebo, measuring improveme…
Phase: PHASE3 • Sponsor: Kexing Biopharm Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could two common drugs boost sleep apnea surgery success?
Disease control Recruiting nowThis study investigates whether two medications—acetazolamide and eszopiclone—can improve sleep apnea outcomes when taken after soft palate surgery. The trial includes adults with moderate to severe obstructive sleep apnea who cannot use CPAP or oral appliances. Researchers will …
Phase: PHASE2 • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for lung cancer patients when targeted drugs stop working
Disease control Recruiting nowThis Phase 3 trial tests a new drug called SYS6010 against standard chemotherapy in 380 people with a specific type of advanced lung cancer (EGFR-mutated) that has stopped responding to targeted therapy. The goal is to see if SYS6010 can delay cancer growth better than chemo. Par…
Phase: PHASE3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a second RSV shot in pregnancy protect more babies?
Disease control Recruiting nowThis study tests whether giving a second dose of an RSV vaccine to pregnant women who already received it in a prior pregnancy is safe and boosts immunity. About 550 women aged 18-49, between 24-36 weeks pregnant, will receive either the vaccine or a placebo. Researchers will tra…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill aims to slow lung scarring in IPF patients
Disease control Recruiting nowThis phase 2 trial tests an oral drug called PIPE-791 in 324 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Participants take either a low or high dose of PIPE-791 or a placebo daily for several months. The main goal is t…
Phase: PHASE2 • Sponsor: Contineum Therapeutics • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: Next-Gen RET inhibitor enters human trials
Disease control Recruiting nowThis study tests a new drug called EP0031 in people with advanced cancers that have a specific genetic change (RET alteration), including non-small cell lung cancer. The trial has two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. About 265 adult…
Phase: PHASE1, PHASE2 • Sponsor: Ellipses Pharma • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for lung cancer: LIBRA trial tests smart drug cocktails
Disease control Recruiting nowThis study tests several new drug combinations in people with advanced non-small cell lung cancer that has spread. The goal is to see if these combinations are safe and can shrink tumors. About 278 adults will take part across 10 countries. The study is open to those with a speci…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo therapy aims to control lung cancer in First-Line patients
Disease control Recruiting nowThis study tests a new drug, BNT327, combined with chemotherapy and other agents in people with advanced non-small cell lung cancer who have not had prior treatment. The trial will enroll about 1,260 participants across multiple sites worldwide. The goal is to see if the combinat…
Phase: PHASE2, PHASE3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill targets tough lung cancers in first human trial
Disease control Recruiting nowThis study tests a new oral drug, BAY 2927088, for people with advanced non-small cell lung cancer that has specific EGFR or HER2 mutations. The trial has four parts to find the safest dose and see if the drug shrinks tumors. About 400 participants will take the drug daily until …
Phase: PHASE1, PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for lung scarring: SOLIS trial tests H01 drug
Disease control Recruiting nowThis study tests a drug called H01 (hymecromone) in adults with interstitial lung disease, a condition that causes lung scarring and makes breathing hard. The goal is to see if H01 can lower a marker of lung damage and improve lung function. Participants take the drug as a tablet…
Phase: PHASE2 • Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug BBT002 aims to tackle COPD and chronic sinusitis in early trial
Disease control Recruiting nowThis study tests a new drug, BBT002, in healthy volunteers and people with chronic obstructive pulmonary disease (COPD) or chronic rhinosinusitis with nasal polyps (CRSwNP). The trial is double-blind and placebo-controlled, meaning some participants get the drug and some get a du…
Phase: PHASE1 • Sponsor: Bambusa Therapeutics • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill aims to keep High-Risk COVID patients out of the hospital
Disease control Recruiting nowThis study tests an oral medication called ibuzatrelvir in adults and teens with COVID-19 who are not hospitalized but have a high risk of becoming severely ill. Participants will receive either the drug or a placebo for 5 days, and researchers will track whether it reduces emerg…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could oxygen or a common drug fix Opioid-Linked sleep apnea?
Disease control Recruiting nowThis study investigates whether oxygen and the drug acetazolamide can help stabilize breathing during sleep in people who take prescription opioids and have sleep apnea. Researchers will measure breathing patterns and sleep quality in 150 veterans. The goal is to find new ways to…
Phase: PHASE1, PHASE2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Double immunotherapy may keep nasopharyngeal cancer at bay
Disease control Recruiting nowThis phase II trial tests whether adding the immunotherapy drug relatlimab to standard nivolumab maintenance therapy can extend the time before cancer grows or spreads in patients with recurrent or metastatic nasopharyngeal cancer linked to Epstein-Barr virus. Participants first …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Oral asthma drug KT-621 tested for Long-Term safety
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of an oral drug called KT-621 in people with asthma. Participants have already completed a previous KT-621 asthma study. The goal is to see how well the drug works over time and if any side effects appear with longer use.
Phase: PHASE2 • Sponsor: Kymera Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Blood test may let some throat cancer patients skip radiation after surgery
Disease control Recruiting nowThis study is for people with HPV-related throat cancer who have surgery to remove the tumor. Normally, some patients also get radiation afterward to lower the risk of cancer coming back. This trial tests whether it's safe to skip that radiation if a blood test two weeks after su…
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New pill for Hard-to-Treat cancers enters first human tests
Disease control Recruiting nowThis early-stage study tests a new oral drug, DEG6498, in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand side effects. Participants take the drug once daily and are closely monitore…
Phase: PHASE1 • Sponsor: Degron Therapeutics Co. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug combo trial aims to fight advanced cancers
Disease control Recruiting nowThis study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Nicotine pouches vs. patches: can they help appalachian smokers quit cigarettes and cut cancer risk?
Disease control Recruiting nowThis trial compares oral nicotine pouches (like ZYN) with standard nicotine replacement therapy (patches and lozenges) to help smokers in rural Appalachia reduce or stop cigarette use. The goal is to lower the high rates of lung and oral cancers linked to smoking in this region. …
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug SLV-154 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called SLV-154 in about 70 people with advanced solid tumors (like head and neck, lung, breast, or ovarian cancer) that have spread. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs …
Phase: PHASE1 • Sponsor: Solve Therapeutics • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug cocktail aims to shrink lung tumors without chemo
Disease control Recruiting nowThis study tests a new drug called telisotuzumab adizutecan (ABBV-400) combined with an immunotherapy drug (budigalimab or pembrolizumab) in people with advanced non-squamous lung cancer who have not had prior treatment. The goal is to find the best dose that is safe and effectiv…
Phase: PHASE1, PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Feeding into the small intestine may reduce reflux and oxygen dips in fragile preterm infants
Disease control Recruiting nowThis pilot trial tests whether feeding directly into the small intestine (transpyloric) is better than feeding into the stomach (gastric) for very preterm infants with bronchopulmonary dysplasia, a chronic lung condition. The study will measure how often babies have low oxygen le…
Phase: NA • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Botox injections studied for movement disorder relief
Disease control Recruiting nowThis study uses botulinum toxin (Botox) injections to treat movement disorders such as dystonia, tremor, and spasticity. Up to 2,000 participants aged 2 and older will receive tailored injections, with doctors trained in proper techniques. The goal is to manage symptoms and build…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug targets Hard-to-Treat lung cancer mutation in major trial
Disease control Recruiting nowThis study tests a new drug, setidegrasib, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific KRAS G12D mutation. The goal is to see if setidegrasib can keep the cancer from growing longer and help people live longer…
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug cocktail could simplify treatment for dangerous lung lining infection
Disease control Recruiting nowThis study tests two different drug combinations for pleural infection, a serious infection of the lung lining that often requires surgery. The standard treatment uses two drugs (alteplase and DNase) given through a chest tube. This trial compares that to a new combination using …
Sponsor: National University of Malaysia • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New mRNA vaccine trial aims to boost immune attack on lung cancer
Disease control Recruiting nowThis early study will test a personalized mRNA vaccine (RGL-270) given together with standard immunotherapy drugs in 40 people with advanced non-small cell lung cancer. The vaccine is custom-made to target unique markers on each person's tumor. The main goal is to check safety an…
Phase: NA • Sponsor: Guangdong Association of Clinical Trials • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Cancer drug adagrasib offers continued hope in rollover trial
Disease control Recruiting nowThis study provides ongoing treatment with the cancer drug adagrasib (BMS-986503) to patients with advanced solid tumors who have already seen benefit in earlier studies. About 170 adults with non-small cell lung cancer, colorectal cancer, or other solid tumors can join if they a…
Phase: PHASE2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for aggressive lung cancer: phase 3 trial launches
Disease control Recruiting nowThis phase 3 trial is testing a new combination of drugs (BMS-986489) plus chemotherapy against a standard treatment (atezolizumab plus chemotherapy) for people with extensive-stage small cell lung cancer, a fast-growing cancer. The study aims to see if the new combo helps people…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a muscle relaxant help fight lung cancer? scientists test papaverine with standard therapy
Disease control Recruiting nowThis trial investigates whether adding papaverine—a drug traditionally used as a muscle relaxant—to standard chemoradiation can improve treatment for people with stage II to III non-small cell lung cancer. Papaverine targets the energy factories inside cancer cells (mitochondria)…
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for Hard-to-Treat lung cancer: targeted drug combo trial launches
Disease control Recruiting nowThis study is testing new drugs called RAS(ON) inhibitors for people with advanced non-small cell lung cancer that has a RAS mutation. The goal is to see if these drugs are safe and can shrink tumors or slow the cancer's growth. About 616 adults who have already tried standard tr…
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug combo aims to boost immune attack on tough lung cancer
Disease control Recruiting nowThis study tests a new drug called ivonescimab, given with standard chemotherapy, for people with extensive-stage small cell lung cancer who haven't had treatment yet. Ivonescimab is a special antibody that helps the immune system fight cancer and may also block blood vessels tha…
Phase: PHASE2 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug ALE.P02 targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called ALE.P02 in people with advanced squamous cell cancers of the lung, head and neck, cervix, or esophagus that have spread or cannot be removed. The goal is to find the safest and most effective dose and see if it can shrink tumors. About 170 adult…
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could melatonin help save newborn brains after oxygen loss?
Disease control Recruiting nowThis early-phase study tests whether adding melatonin to standard cooling therapy can improve brain outcomes in newborns with hypoxic-ischemic encephalopathy (HIE), a condition caused by oxygen loss at birth. About 70 full-term infants will receive different doses of melatonin to…
Phase: EARLY_PHASE1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New immune drug STK-012 takes on tough lung cancers
Disease control Recruiting nowThis study tests a new drug called STK-012, which is designed to boost the immune system's ability to fight cancer. It is being tested alone or with standard treatments (pembrolizumab, pemetrexed, carboplatin) in people with advanced solid tumors, especially those with a type of …
Phase: PHASE1, PHASE2 • Sponsor: Synthekine • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New asthma pill shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests an oral drug called KT-621 in 264 adults with moderate to severe eosinophilic asthma that is not well controlled by current treatments. Participants will take either KT-621 or a placebo daily for several weeks. Researchers will measure changes in lung function an…
Phase: PHASE2 • Sponsor: Kymera Therapeutics, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug cocktail aims to extend life in tough lung cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding a maintenance drug (sacituzumab tirumotecan) after initial chemo-immunotherapy improves survival in people with metastatic squamous non-small cell lung cancer. About 851 participants will receive pembrolizumab plus chemotherapy, then either…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug aimed at Hard-to-Treat lung cancer enters Mid-Stage trial
Disease control Recruiting nowThis phase 2 trial is testing three different doses of an investigational drug called telisotuzumab vedotin in about 150 adults with a specific type of advanced lung cancer (non-small cell lung cancer that has high levels of a protein called c-Met and no EGFR mutation). The drug …
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for lung cancer patients: experimental drug takes on standard therapy
Disease control Recruiting nowThis study tests a new drug called rilvegostomig against the standard drug pembrolizumab, both given with chemotherapy, as a first treatment for people with advanced non-squamous lung cancer that has spread. About 878 adults whose tumors have a specific protein (PD-L1) will take …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug MK-4884 tested for safety in advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how …
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New asthma drug candidate enters first human safety tests
Disease control Recruiting nowThis early-stage study tests a new experimental drug, PF-08103402, for the first time in people. It includes healthy adults and adults with mild-to-moderate asthma to check safety, how the drug moves through the body, and whether food affects its absorption. Participants take the…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New combo aims to stop lung cancer return after surgery
Disease control Recruiting nowThis study tests whether adding the drug MK-2870 to standard immunotherapy (pembrolizumab) after surgery can help prevent lung cancer from coming back. It is for people with stage II to IIIB non-small cell lung cancer whose tumor did not fully disappear after chemotherapy and imm…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Dog allergy vaccine shows promise in small swedish trial
Disease control Recruiting nowThis study tests a dog allergy immunotherapy called Alutard SQ Dog in 40 adults with moderate-to-severe dog allergy. Participants receive increasing doses over 13 weeks, then maintenance shots every 6-8 weeks for a year. Their symptoms and lung function are measured before and af…
Phase: PHASE4 • Sponsor: Karolinska Institutet • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can custom ventilation save more ARDS lungs?
Disease control Recruiting nowThis study tests whether a personalized breathing machine strategy can improve survival in people with acute respiratory distress syndrome (ARDS), a severe lung condition. About 1,100 adults on ventilators will be randomly assigned to either standard care or a precision approach …
Phase: PHASE3 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Feeding tube placement may improve breathing in preterm babies
Disease control Recruiting nowThis study tests whether feeding preterm infants with chronic lung disease through a tube placed past the stomach (into the small intestine) helps their breathing more than feeding through a tube in the stomach. About 50 high-risk preterm babies born before 32 weeks will receive …
Phase: NA • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New allergy shot aims to tame mugwort season in just four weeks
Disease control Recruiting nowThis Phase 2 trial tests PollenVax, a new immunotherapy for people with moderate-to-severe allergic rhinitis caused by mugwort pollen. The treatment is given as four weekly shots before the pollen season. Researchers will compare symptom scores and medication use between the Poll…
Phase: PHASE2 • Sponsor: Kazakh National Agrarian University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New combo therapy targets Hard-to-Treat RAS-Mutant cancers
Disease control Recruiting nowThis study tests whether combining experimental RAS(ON) inhibitors with ivonescimab (an immunotherapy) can shrink or control advanced solid tumors that have a RAS mutation. About 370 adults with cancers like non-small cell lung cancer or colorectal cancer will receive these drugs…
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat cancers with genetic flaw
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called BMS-986504 alongside standard cancer treatments in 60 people with advanced cancers that have lost a gene called MTAP. The cancers include mesothelioma, stomach/esophageal cancer, and bladder cancer. The main goal is to…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill targets Hard-to-Treat KRAS cancers in first human trial
Disease control Recruiting nowThis early-phase trial is testing an experimental oral drug called KST-6051 in adults with advanced or metastatic solid tumors that have a KRAS mutation, including certain lung, pancreatic, and colorectal cancers. The main goal is to check the drug's safety and how the body proce…
Phase: PHASE1 • Sponsor: Kestrel Therapeutics, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New cancer drug YL211 enters first human tests
Disease control Recruiting nowThis early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…
Phase: PHASE1 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Global study checks if triple inhaler really works for COPD patients
Disease control Recruiting nowThis study follows 1,400 adults with moderate to severe COPD who are starting Breztri/Trixeo, a triple-combination inhaler. Researchers will track changes in symptoms and quality of life over 12 months in real-world clinics across Latin America, Asia, and the Middle East & Africa…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Depth camera could guide oxygen therapy and prevent intubation in respiratory failure
Disease control Recruiting nowThis phase 3 trial tests whether adjusting the flow rate of high-flow oxygen therapy based on lung volume measurements from a depth camera can reduce the need for intubation in intensive care patients with hypoxemic respiratory failure. About 406 participants will be randomly ass…
Phase: PHASE3 • Sponsor: University Hospital, Brest • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Fetal balloon surgery aims to save babies with rare birth defect
Disease control Recruiting nowThis study tests a fetal surgery called FETO for severe congenital diaphragmatic hernia (CDH), a condition where a hole in the diaphragm allows organs to crowd the lungs. Researchers will place a tiny balloon in the fetal windpipe to encourage lung growth, then remove it before b…
Phase: NA • Sponsor: Vincent Duron • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Immune cells supercharged to fight advanced cancers
Disease control Recruiting nowThis study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or stopped responding to standard therapy. OBX-115 uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified in the…
Phase: PHASE1, PHASE2 • Sponsor: Obsidian Therapeutics, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New radiation approach aims to safely treat Hard-to-Reach lung tumors
Disease control Recruiting nowThis early-stage study tests a personalized radiation technique called PULSAR for lung cancers located near the center of the chest. The goal is to make treatment safer while still effectively controlling the tumor. About 30 adults with primary or metastatic lung cancer will rece…
Phase: EARLY_PHASE1 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for lung transplant patients: drug may slow chronic rejection
Disease control Recruiting nowThis Phase 3 trial tests an oral drug called belumosudil in adults who have chronic lung allograft dysfunction (CLAD) after a bilateral lung transplant. CLAD is a form of chronic rejection that slowly worsens lung function. The study compares belumosudil to a placebo, both given …
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug CR-001 enters human trials
Disease control Recruiting nowThis study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.
Phase: PHASE1, PHASE2 • Sponsor: Crescent Biopharma, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New weekly shot could help sleep apnea and weight loss
Disease control Recruiting nowThis study tests a once-weekly injection called NNC0487-0111 in 300 adults with overweight or obesity and moderate-to-severe obstructive sleep apnea who use a breathing device. The goal is to see if the drug helps with weight loss and reduces breathing pauses during sleep. Partic…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New inhaled drug could help lung disease patients breathe easier and walk farther
Disease control Recruiting nowThis study tests an inhaled medicine called L606 for people with high blood pressure in the lungs due to lung disease. About 344 adults will be randomly assigned to receive L606 or a placebo. The main goal is to see if L606 helps them walk farther in six minutes and delays worsen…
Phase: PHASE3 • Sponsor: Liquidia Technologies, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: enhertu studied in 20+ tumor types
Disease control Recruiting nowThis study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Pioneering fetal surgery aims to save babies born with a hole in their diaphragm
Disease control Recruiting nowThis study tests a procedure called FETO, done during pregnancy, for babies with a severe congenital diaphragmatic hernia (CDH). The goal is to see if FETO helps more babies survive after birth and have fewer long-term health issues compared to standard care. The study will enrol…
Phase: NA • Sponsor: Dr Erin Perrone • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New mRNA vaccine combo takes on tough lung cancer in phase 2 trial
Disease control Recruiting nowThis Phase 2 trial tests whether adding a personalized mRNA vaccine (V940) to standard pembrolizumab and chemotherapy helps people with newly diagnosed metastatic squamous non-small cell lung cancer live longer and keep the cancer from growing. About 180 participants will receive…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New lung cancer drug pumitamig takes on standard therapy in major trial
Disease control Recruiting nowThis phase 3 study compares the experimental drug pumitamig to the standard treatment durvalumab in people with stage III lung cancer that cannot be removed by surgery. Participants must have finished chemoradiation without their cancer getting worse. The main goal is to see if p…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to fight tough lung cancer
Disease control Recruiting nowThis study tests two experimental drugs, gocatamig and ifinatamab deruxtecan, alone or with standard chemotherapy and immunotherapy, for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors. About 170 participants…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Lung cancer vaccine trial aims to stop tumors from coming back
Disease control Recruiting nowThis study tests whether adding an experimental mRNA vaccine (V940) to the immunotherapy drug pembrolizumab (Keytruda) can keep lung cancer from returning after surgery. It includes 680 people with stage II to IIIB non-small cell lung cancer whose tumors did not fully respond to …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Lung cancer Patients' own immune cells could shrink tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests a personalized therapy called LN-145, made from a patient's own tumor-fighting immune cells. Researchers take a sample of the tumor, grow the immune cells in a lab, and then infuse them back into the patient after a short course of chemotherapy. The goal …
Phase: PHASE2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug TAK-928 takes on tough lung cancer in major trial
Disease control Recruiting nowThis phase 3 trial tests TAK-928, a drug designed to activate T cells inside tumors, against standard chemotherapy (docetaxel) in 600 adults with advanced non-small cell lung cancer that has worsened after prior treatments. The goal is to see if TAK-928 can shrink tumors or help …
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New injectable drug shows promise for tough lung cancer
Disease control Recruiting nowThis early-phase trial is testing a drug called tarlatamab, given as a shot under the skin, for people with extensive stage small cell lung cancer that has worsened after standard chemotherapy. The main goals are to check safety and side effects, and to see how the drug behaves i…
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Leukemia drug repurposed to fight resistant lung cancer
Disease control Recruiting nowThis early-stage trial tests gilteritinib, a drug already approved for leukemia, in 30 people with stage IV ALK-positive non-small cell lung cancer that has stopped responding to other treatments. The main goal is to find the safest dose and check for side effects. Researchers ho…
Phase: PHASE1 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New targeted drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, BAY 3713372, for people with solid tumors that have a specific genetic deletion called MTAP. The drug is designed to kill cancer cells while sparing normal cells. The trial will first find a safe dose, then test how well it works in up to 450 particip…
Phase: PHASE1, PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Could earlier breathing help in ALS? new trial aims to find out
Disease control Recruiting nowThis study tests whether starting non-invasive ventilation (a breathing machine) earlier than usual helps people with ALS. Researchers will use a prediction tool to find those at high risk of breathing problems within 6 months. 48 participants will be randomly assigned to early N…
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Could a single nasal spray stop asthma Flare-Ups from colds?
Disease control Recruiting nowThis study tests whether a single dose of a nasal spray called ETH47 can reduce asthma symptoms caused by a common cold virus (rhinovirus). Fifty adults with stable asthma will receive either the spray or a placebo and then be exposed to the virus in a controlled setting. Researc…
Phase: PHASE2 • Sponsor: Ethris GmbH • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: first human trial of ERAS-0015 begins
Disease control Recruiting nowThis early-stage trial tests a new oral drug called ERAS-0015, alone or with other cancer drugs, in 600 adults with advanced solid tumors that have certain RAS mutations. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Researc…
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo aims to stop KRAS-Mutant lung cancer from coming back
Disease control Recruiting nowThis Phase 3 trial is testing whether adding an experimental drug called calderasib (MK-1084) to standard immunotherapy (pembrolizumab) can keep non-small cell lung cancer from returning after surgery. The study enrolls 400 people with a specific KRAS G12C mutation whose cancer w…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill targets rare cancer mutation in early trial
Disease control Recruiting nowThis study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…
Phase: PHASE1, PHASE2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New asthma drug could help kids breathe easier
Disease control Recruiting nowThis study tests whether tezepelumab, an injectable drug, can reduce severe asthma attacks in children aged 5 to 11 with hard-to-control asthma. About 231 kids will receive either tezepelumab or a placebo, alongside their usual asthma medicines. The main goal is to see if the dru…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill shows promise for tough lung cancer mutation
Disease control Recruiting nowThis phase 2b trial tests an oral drug called zipalertinib in 220 people with advanced non-small cell lung cancer that has certain EGFR mutations. The goal is to see if the drug can shrink tumors and how safe it is. Participants take the drug daily, and researchers will monitor t…
Phase: PHASE2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Simple spacer could cut hospital visits for seniors with lung disease
Disease control Recruiting nowThis study tests whether adding a spacer device to standard triple inhaler therapy can reduce serious flare-ups in older adults (65+) with asthma or COPD who are at high risk. 380 participants will either use the spacer with their inhaler or stick with the inhaler alone. The goal…
Phase: NA • Sponsor: First Affiliated Hospital of Ningbo University • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Lung cancer combo aims to wipe out tumors before surgery
Disease control Recruiting nowThis phase 2 trial is testing whether giving the immunotherapy drug pembrolizumab (Keytruda) along with chemotherapy before surgery can eliminate all signs of cancer in people with resectable stage II to IIIB non-small cell lung cancer. About 60 participants will receive the comb…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for small cell lung cancer: immunotherapy after surgery
Disease control Recruiting nowThis phase 2 trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy after surgery can help prevent small cell lung cancer from coming back. About 65 adults who had their cancer completely removed will receive the combination for 12 weeks, then durva…
Phase: PHASE2 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for KRAS lung cancer: targeted pill plus immunotherapy in Late-Stage trial
Disease control Recruiting nowThis phase 3 trial tests whether adding the targeted pill calderasib (MK-1084) to the immunotherapy durvalumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 310 participants who have finished chemotherapy and radiation …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New inhaled powder for lung blood pressure condition tested in 80 patients
Disease control Recruiting nowThis study is testing the safety of an inhaled dry powder form of treprostinil (LIQ861) for people with pulmonary hypertension (high blood pressure in the lungs) due to lung disease. About 80 adults will take the drug using a special inhaler, and researchers will monitor for side…
Sponsor: Liquidia Technologies, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Biomarker-Guided combo aims to outsmart tough cancers
Disease control Recruiting nowThis phase II trial is testing whether the combination of cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head and neck cancers that have stopped responding to prior immunotherapy. Researchers are also checking if t…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New device zaps lung tumors through a scope before surgery
Disease control Recruiting nowThis study tests a new device that uses microwave energy to destroy lung tumors during a bronchoscopy, before the patient has surgery to remove the tumor. The goal is to see if the device is safe and works well in 30 people with confirmed lung cancer who are already scheduled for…
Sponsor: Creo Medical Limited • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New weekly shot could help sleep apnea without CPAP
Disease control Recruiting nowThis study tests a once-weekly injection called NNC0487-0111 in 300 adults with overweight or obesity and moderate-to-severe obstructive sleep apnea who do not use a CPAP machine. The goal is to see if the drug helps with weight loss and reduces breathing pauses during sleep. Par…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New lung cancer drug pumitamig takes on standard therapy in major trial
Disease control Recruiting nowThis phase 3 trial compares a new drug called pumitamig to the standard drug pembrolizumab as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1 (at least 50%). The study will enroll 750 participants and measure ho…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Experimental immune therapy aims to reduce deaths in severe pneumonia
Disease control Recruiting nowThis study tests whether a single dose of an experimental immune cell therapy called agenT-797, given alongside standard care, can lower the risk of death in adults with severe pneumonia and breathing failure. About 90 people in intensive care will receive either agenT-797 or a p…
Phase: PHASE2 • Sponsor: MiNK Therapeutics • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Leukemia drug repurposed for hard-to-treat lung cancer in early trial
Disease control Recruiting nowThis early-phase study tests gilteritinib, a drug already approved for a type of leukemia, in about 40 adults with ALK-positive non-small cell lung cancer whose tumors no longer respond to standard ALK inhibitors. Participants take gilteritinib tablets daily in 28-day cycles. The…
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat lung cancer subtype
Disease control Recruiting nowThis study tests whether adding a new drug called navlimetostat to standard immunotherapy (pembrolizumab) and chemotherapy helps people with a specific genetic form of advanced lung cancer (MTAP deletion) live longer without their cancer worsening. About 590 participants will be …
Phase: PHASE2, PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New inhaler propellant tested in mild asthma study
Disease control Recruiting nowThis study tests whether a new propellant (HFA-152a) in salbutamol inhalers works as well as the current one (HFA-134a) for people with mild asthma. 84 adults aged 18-65 will receive single doses of the inhaler or a placebo. The main goal is to measure how well the inhaler protec…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New triple inhaler aims to cut heart and lung emergencies in COPD
Disease control Recruiting nowThis Phase 3 trial is testing whether a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) can reduce serious heart and lung events in people with COPD who are at elevated risk. About 5,250 participants aged 40–80 will receive either the triple therapy or a d…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New breathing device could help tiny preemies stay off ventilators
Disease control Recruiting nowThis trial tests whether a new breathing support method called NIV-NAVA helps very preterm infants (born at 23-28 weeks) avoid breathing failure after being taken off a ventilator. About 478 infants will be randomly assigned to receive either NIV-NAVA or standard non-synchronized…
Phase: NA • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug XTX301 takes on advanced cancers in first human trial
Disease control Recruiting nowThis study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could diabetes pills boost cancer immunotherapy?
Disease control Recruiting nowThis phase 2 trial is testing whether adding common diabetes drugs (metformin or rosiglitazone) to standard immunotherapy (nivolumab or pembrolizumab) can improve treatment for several advanced solid tumors, including melanoma, lung cancer, and liver cancer. About 72 participants…
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to boost radiation success in EBV-related throat cancer
Disease control Recruiting nowThis study tests whether giving three drugs (gemcitabine, docetaxel, and toripalimab) before standard radiation can safely improve outcomes for people with a specific throat cancer caused by the Epstein-Barr virus. About 24 adults with advanced but not spread cancer will receive …
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New combo therapy aims to make inoperable lung cancer operable
Disease control Recruiting nowThis study tests whether a special radiation method (SFRT) given alongside immunotherapy (tislelizumab) and standard chemotherapy can shrink stage III lung tumors that cannot be surgically removed. The goal is to see if this combination makes more patients eligible for surgery. T…
Phase: PHASE2, PHASE3 • Sponsor: Second Affiliated Hospital of Nanchang University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Can one infusion speed recovery from sickle cell lung crisis?
Disease control Recruiting nowThis study tests whether a single dose of tocilizumab, an anti-inflammatory drug, can help children and adults with sickle cell disease recover faster from acute chest syndrome—a serious lung condition. Participants receive either the drug or a placebo, and researchers measure ho…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Eco-Friendly asthma inhaler put to the test
Disease control Recruiting nowThis study compares a new version of an asthma inhaler that uses a climate-friendly propellant to the current version. About 780 adults with mild to moderate asthma will try both inhalers to see if they work equally well. The goal is to ensure the greener option is just as effect…
Phase: PHASE2 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New pill targets Hard-to-Treat KRAS cancers in first human trial
Disease control Recruiting nowThis early-stage trial tests a new oral drug called AMG 410, alone or with other medicines, in adults with advanced solid tumors that have KRAS gene changes. The study aims to find a safe dose and check for side effects. About 434 participants will take part across multiple dose …
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New radiation 'Smart Bomb' targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new type of radiation therapy that seeks out and attacks cancer cells while sparing healthy tissue. It's for people with advanced breast, lung, stomach, or bladder cancer who have run out of standard options. The study will check if the treatme…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Immunotherapy after Chemo-Radiation shows promise for lung cancer
Disease control Recruiting nowThis study looks at whether the immunotherapy drug durvalumab can help people with limited-stage small-cell lung cancer when given after chemoradiation. Researchers will track 200 patients in China to see how long the cancer stays under control and how safe the treatment is. The …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New combo aims to reboot immunotherapy in resistant cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called BI-1206, given alongside the immunotherapy pembrolizumab, in adults with advanced solid tumors that have stopped responding to prior anti-PD-1/PD-L1 treatment. The study aims to find the safest dose and check for early signs of tumor…
Phase: PHASE1, PHASE2 • Sponsor: BioInvent International AB • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New combo inhaler aims to ease asthma symptoms
Disease control Recruiting nowThis phase 3 trial tests a new inhaler that combines fluticasone (an anti-inflammatory) and albuterol (a fast-acting bronchodilator) for people 12 and older with asthma. Over 4 weeks, researchers will measure lung function and safety in 724 participants. The goal is to see if the…
Phase: PHASE3 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to shrink mouth cancer before surgery
Disease control Recruiting nowThis phase 2 trial tests whether giving two drugs, cemiplimab and cetuximab, before salvage surgery can help control recurrent oral cavity squamous cell carcinoma. The study involves 17 adults whose cancer has returned at least 3 months after prior treatment. Researchers will mon…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Cholesterol-Lowering drug may boost lung cancer immunotherapy
Disease control Recruiting nowThis phase 2 trial tests whether adding tafolecimab (a cholesterol-lowering drug) to standard chemotherapy and the immunotherapy sintilimab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 40 adults who have not had prior tr…
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Last-Resort drug access opens for ALK-Positive cancer patients
Disease control AVAILABLEThis program offers early access to the investigational drug neladalkib for people with advanced ALK-positive lung cancer or other ALK-positive solid tumors who have run out of standard treatment options and cannot join a clinical trial. Participants must be at least 18 years old…
Sponsor: Nuvalent Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug GEn-1124 tested for severe lung failure
Disease control Recruiting nowThis study tests a new drug called GEn-1124 in 52 adults with acute respiratory distress syndrome (ARDS), a severe lung condition. The drug is given as an IV infusion twice daily for 5 days, starting as soon as possible after diagnosis. The main goal is to check if the drug is sa…
Phase: PHASE2 • Sponsor: GEn1E Lifesciences • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cancer drug BBO-10203 enters first human trials
Disease control Recruiting nowThis early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New proton therapy could outshine standard radiation for deadly cancer complication
Disease control Recruiting nowThis phase III trial tests whether proton craniospinal irradiation (pCSI) can improve survival compared to standard involved-field radiation therapy (IFRT) for patients with breast or non-small cell lung cancer that has spread to the lining of the brain and spinal cord (leptomeni…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug aims to shrink Hard-to-Treat lung cancers
Disease control Recruiting nowThis phase 2 trial tests BI 764532 (obrixtamig), an antibody-like drug designed to help the immune system attack cancer cells. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to prior treatments. The study compares two…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New immunotherapy combo aims to improve First-Line lung cancer treatment
Disease control Recruiting nowThis study tests whether a new drug called SCTB41, when combined with chemotherapy, works better than the standard immunotherapy tislelizumab plus chemotherapy for people with advanced non-small cell lung cancer that has no targetable genetic mutations. The trial has two parts: a…
Phase: PHASE2, PHASE3 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New lung fibrosis pill tested for Long-Term safety in 1,700 patients
Disease control Recruiting nowThis study tests the long-term safety of the drug nerandomilast in people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). All 1,700 participants have already taken the drug in a previous study. They will take nerandomilast tablets for up to 1 yea…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New asthma drug aims to stop attacks before they start
Disease control Recruiting nowThis study tests whether depemokimab, an injected biologic drug, can reduce severe asthma attacks and help patients achieve remission when added to standard care. About 456 adults and adolescents with type 2 asthma at risk of flare-ups will receive either depemokimab or a placebo…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill aims to cut dangerous lung Flare-Ups in bronchiectasis
Disease control Recruiting nowThis study tests a daily pill called BI 1291583 (Verducatib) in 1755 adults and teens with bronchiectasis, a lung condition causing frequent infections and coughing. Participants take either the drug or a placebo for up to 76 weeks. The main goal is to see if the drug reduces the…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug duo aims to shrink tough lung cancers
Disease control Recruiting nowThis study is testing two experimental drugs, BNT324 and BNT327, together in people with advanced lung cancer that has spread or come back. BNT324 targets and delivers a toxin to cancer cells, while BNT327 helps the immune system attack tumors and cuts off their blood supply. The…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for lung scarring: AZD8965 enters Mid-Stage trial
Disease control Recruiting nowThis phase IIb study tests three doses of AZD8965 against a placebo in 359 adults with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. The main goal is to see if AZD8965 can slow the decline in lung function over 24 weeks. Participants may also be taking standard IP…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Caffeine trial aims to keep preterm babies breathing safely at home
Disease control Recruiting nowThis study tests whether giving caffeine citrate to moderately preterm infants for 28 days after hospital discharge can prevent apnea (breathing pauses) that lead to sick visits. About 340 babies in Zambia will receive either caffeine or a placebo daily. Researchers will also che…
Phase: PHASE4 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for lung cancer: drug cocktail trial launches
Disease control Recruiting nowThis study tests several new drug combinations, including pembrolizumab (an immunotherapy), with or without chemotherapy, in people with advanced non-small cell lung cancer who have not had prior treatment. The goal is to see if these combinations can shrink tumors and control th…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for immunocompromised patients with severe parainfluenza
Disease control Recruiting nowThis study tests an experimental drug called DAS181 in people with weakened immune systems who have a serious lung infection caused by parainfluenza virus. The goal is to see if the drug helps them breathe without extra oxygen and reduces the risk of death. About 274 participants…
Phase: PHASE3 • Sponsor: Ansun Biopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Cancer patients on targeted therapy get extended safety monitoring
Disease control Recruiting nowThis study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for aggressive lung cancer: experimental drug combo enters final testing
Disease control Recruiting nowThis study tests whether adding the experimental drug obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combination…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Lung cancer breakthrough? new drug cocktail trial aims to boost surgery success
Disease control Recruiting nowThis study tests several drug combinations given before and after surgery for early-stage non-small cell lung cancer. About 630 participants will receive immunotherapy drugs like durvalumab along with chemotherapy or other targeted agents. The goal is to see if these combos can e…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Asthma care goes to school: new study tests In-School treatment to cut attacks
Disease control Recruiting nowThis study tests whether school-based health centers can improve asthma care for 400 children with uncontrolled asthma from underserved communities. The program includes guideline-based assessments, directly observed preventive medication, and self-management support. The goal is…
Phase: NA • Sponsor: State University of New York at Buffalo • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New biologic drug aims to cut COPD attacks in half
Disease control Recruiting nowThis Phase 3 study tests whether tezepelumab, a biologic drug, can reduce moderate to severe COPD flare-ups in adults aged 40-80. About 990 participants will receive either tezepelumab or a placebo as a shot under the skin. The main goal is to see if the drug lowers the number of…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New TB cocktails aim to speed up recovery
Disease control Recruiting nowThis study tests new combinations of drugs for adults with lung tuberculosis (TB). The goal is to see if these new regimens work faster and are safer than the current standard treatment. About 315 participants will receive either an experimental drug combo or the usual care for 8…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Breakthrough asthma drug may let patients ditch puffers
Disease control Recruiting nowThis phase 3 trial is testing whether people with severe asthma who take the drug Tezepelumab can safely cut back on their other daily asthma medications without losing control of their symptoms. About 400 participants aged 12 to 80 will be enrolled. The goal is to see if they ca…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immune cells tailored to attack lung cancer show promise in early trial
Disease control Recruiting nowThis trial investigates whether specially engineered T cells can safely target and fight lung cancer. Participants have advanced or relapsed lung cancer and receive a single infusion of their own T cells that have been trained to recognize cancer-specific markers. The study aims …
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Electric field therapy device takes on metastatic lung cancer in major trial
Disease control Recruiting nowThis Phase 3 trial tests whether adding a wearable device that delivers electric fields (TTFields) to standard immunotherapy and chemotherapy improves survival in people with metastatic non-small cell lung cancer. About 734 participants who have not had prior treatment for their …
Phase: PHASE3 • Sponsor: NovoCure GmbH • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Precision radiation may boost lung cancer treatment
Disease control Recruiting nowThis phase 3 trial tests whether adding a precise, high-dose radiation treatment (SBRT) to standard chemoradiation and immunotherapy improves survival for people with locally advanced non-small cell lung cancer that cannot be surgically removed. About 474 participants will be ran…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to outperform standard lung cancer therapy
Disease control Recruiting nowThis phase 3 trial is testing whether a combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-squamous lung cancer whose tumors have PD-L1 levels of…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
First-in-Human trial launches for Off-the-Shelf CAR-NK therapy against tough cancers
Disease control Recruiting nowThis early-stage trial is testing a new cell therapy called NEUK203-13 for people with advanced small cell lung cancer or other neuroendocrine tumors that have not responded to standard treatments. The therapy uses immune cells (NK cells) made from stem cells and engineered to ta…
Phase: PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Double drug attack on tough lung cancer shows promise
Disease control Recruiting nowThis study tests a combination of two targeted drugs—sotorasib and trastuzumab deruxtecan—in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the combo works at shrinking tumors. About 37 …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for Hard-to-Treat cancers? early trial launches
Disease control Recruiting nowThis early-phase trial is testing a new drug called BMS-986517 in about 315 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that the drug …
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for Hard-to-Treat cancers: first human trial launches
Disease control Recruiting nowThis early-stage study tests a new drug called azirkitug, alone or with other cancer medicines, in people with advanced solid tumors like lung, head/neck, and pancreatic cancers. The goal is to find safe doses and check side effects. About 694 adults will take part worldwide, rec…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New Two-Step valve procedure aims to cut lung collapse risk in emphysema patients
Disease control Recruiting nowThis study compares two ways of placing Zephyr valves in the lungs of people with severe emphysema (a type of COPD). The standard method treats the entire lobe in one session, but about 27% of patients develop a collapsed lung (pneumothorax). The experimental method spreads the v…
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
MRNA vaccine technology takes on advanced cancers
Disease control Recruiting nowThis study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Smart drug missiles take aim at Hard-to-Treat lung cancer
Disease control Recruiting nowThis Phase 2 study tests two new antibody-drug conjugates (R-DXd and I-DXd) against standard chemotherapy in 96 people with advanced nonsquamous non-small cell lung cancer that has worsened after prior immunotherapy and chemotherapy. These 'guided missiles' deliver a cancer-killi…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could caffeine help save newborn brains? major trial launches
Disease control Recruiting nowThis study tests whether giving caffeine to newborns with hypoxic ischemic encephalopathy (HIE) can reduce death or long-term disability. HIE is a brain injury caused by lack of oxygen around birth. The trial will enroll 830 full-term infants and give them either caffeine or a pl…
Phase: PHASE3 • Sponsor: NICHD Global Network for Women's and Children's Health • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to boost lung cancer treatment
Disease control Recruiting nowThis early-stage trial is testing a new drug called JNJ-86974680, alone or with another drug (cetrelimab) and radiation, in people with advanced non-small cell lung cancer. The main goal is to find a safe and tolerable dose. About 126 participants will be enrolled. The study is c…
Phase: PHASE1 • Sponsor: Johnson & Johnson Enterprise Innovation Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can acupuncture boost lung cancer treatment? new trial aims to find out
Disease control Recruiting nowThis study tests whether adding electro-acupuncture to standard first-line treatment (PD-1 inhibitors plus chemotherapy) helps people with metastatic non-small cell lung cancer. About 424 participants will receive either real or sham acupuncture alongside their cancer therapy. Th…
Phase: NA • Sponsor: Guangzhou University of Traditional Chinese Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Real-World study tests Benralizumab's impact on severe asthma control
Disease control Recruiting nowThis study follows 300 adults with severe eosinophilic asthma who are prescribed benralizumab as part of their normal care in Germany. Researchers will track changes in asthma control, lung function, and medication use over one year. The goal is to see how the drug performs outsi…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail aims to shrink Hard-to-Treat lung tumors
Disease control Recruiting nowThis phase 2 trial tests a combination of two drugs—lucankizumab and goleirex—as a first treatment for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The study will enroll 43 participants to see if the combo shrinks tumors and how safe it …
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug trial aims to improve lung function in fibrosis patients
Disease control Recruiting nowThis study tests a new medicine called BI 765423 in 71 adults with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing problems. Participants receive either the drug or a placebo by infusion every four weeks for about 3 months. The main goal is …
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can a common steroid stop lung fluid from coming back?
Disease control Recruiting nowThis pilot study tests whether the steroid prednisone can prevent recurrent pleural effusions (fluid buildup around the lungs) in people with non-specific pleuritis. Forty adults will be randomly assigned to take prednisone daily for 4 weeks or receive no steroid. The study lasts…
Phase: EARLY_PHASE1 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New inhaled antibody could help asthma sufferers breathe easier
Disease control Recruiting nowThis study tests whether an inhaled drug called LQ036 can improve lung function and asthma control in people whose asthma is not well managed with current treatments. About 216 participants will inhale the drug or a placebo once daily for 24 weeks. The main goal is to see if LQ03…
Phase: PHASE2 • Sponsor: Shanghai Novamab Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can spreading out radiation beat a single dose for brain tumors?
Disease control Recruiting nowThis Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New asthma drug brenipatide enters Mid-Stage trial
Disease control Recruiting nowThis study tests whether the experimental drug brenipatide can reduce asthma attacks and improve breathing in adults whose moderate-to-severe asthma is not well controlled by current treatments. About 531 participants will receive either brenipatide or a placebo for 52 weeks. The…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug RSC-1255 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests an experimental drug called RSC-1255, given alone or with hydroxychloroquine, in people with advanced solid tumors (like lung, colon, or pancreatic cancer) who have run out of standard options. The study has two parts: first, finding a safe dose, and …
Phase: PHASE1 • Sponsor: RasCal Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New weekly shot aims to treat sleep apnea and obesity together
Disease control Recruiting nowThis phase 3 trial tests a weekly injection called eloralintide in 800 adults with moderate-to-severe obstructive sleep apnea who are also overweight or have obesity. The study looks at whether the drug can improve sleep apnea symptoms and help with weight loss. Participants are …
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New shot could tame COPD Flare-Ups in severe patients
Disease control Recruiting nowThis Phase 3 trial tests whether tezepelumab, a biologic drug given as a shot, can reduce the number of moderate to severe COPD flare-ups in adults aged 40 to 80. About 990 participants with moderate to very severe COPD will receive either tezepelumab or a placebo for up to 76 we…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New antibody drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called LY4175408, which is designed to seek out and attack cancer cells that have a specific marker (PTK7). The study includes 240 people with advanced lung, endometrial, or triple-negative breast cancers that have not responded to standard…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New lung cancer pill takes on chemo in major trial
Disease control Recruiting nowThis Phase 3 trial is testing a new oral drug called daraxonrasib (RMC-6236) against the standard chemotherapy docetaxel in about 590 people with advanced non-small cell lung cancer that has a specific RAS mutation. Participants must have already tried at least one prior treatmen…
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New antibody M0324 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug aims to halt lung damage in autoimmune patients
Disease control Recruiting nowThis study tests whether the drug nerandomilast can slow lung scarring in people with autoimmune diseases like rheumatoid arthritis or scleroderma. About 400 adults whose lung function hasn't improved with standard treatment will take either nerandomilast or a placebo twice daily…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for aggressive lung cancer: Immune-Boosting combo trial launches
Disease control Recruiting nowThis phase 3 trial tests whether adding the drug tarlatamab to standard chemotherapy and immunotherapy helps people with extensive-stage small-cell lung cancer live longer. About 330 participants will be randomly assigned to receive either the new combination or standard treatmen…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can a smartphone app help teens with chronic illnesses manage weight?
Disease control Recruiting nowThis study is testing a mobile app called Adhera Caring Digital Program for Obesity (ACDP-O) in 280 families. The app provides personalized education, mental health monitoring, and wearable device integration to support weight management and well-being in adolescents and young ad…
Phase: NA • Sponsor: Adhera Health, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New RSV drug trial aims to protect vulnerable adults
Disease control Recruiting nowThis study tests an experimental antiviral drug called S-337395 in adults with RSV who are at high risk for severe illness. Participants must have symptoms for less than 72 hours and a confirmed RSV infection. The goal is to see if the drug can lower the amount of virus in the bo…
Phase: PHASE2 • Sponsor: Shionogi • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New weekly shot could fight deadly mould infections with fewer side effects
Disease control Recruiting nowThis Phase 2 trial tests whether a new drug called EL219 (Turletricin) is safe and effective for early treatment of invasive mould infections in people with weakened immune systems, such as those who have had a bone marrow transplant. About 60 participants will receive either EL2…
Phase: PHASE2 • Sponsor: Elion Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for tough lung cancer: phase 3 trial launches
Disease control Recruiting nowThis phase 3 trial tests whether the drug sacituzumab govitecan (Trodelvy) helps people with extensive stage small cell lung cancer live longer compared to standard treatments. About 695 participants who have already had one round of chemotherapy will be randomly assigned to rece…
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered immune cells take on tough lung cancer
Disease control Recruiting nowThis study tests a new treatment called DJI136, which uses a patient's own immune cells engineered to target a protein (DLL3) found on small cell lung cancer cells. The trial enrolls 80 adults with extensive-stage small cell lung cancer whose disease has progressed after standard…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for tough lung cancer: targeted drug ZL-1310 enters final testing
Disease control Recruiting nowThis Phase 3 trial tests ZL-1310, a drug that delivers chemotherapy directly to cancer cells, in people with small cell lung cancer that has returned after initial treatment. About 480 participants will receive either ZL-1310 or one of three standard treatments. The study aims to…
Phase: PHASE3 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New balloon could keep sinus patients out of the operating room
Disease control Recruiting nowThis study tests whether a balloon coated with the drug paclitaxel, used during standard sinus surgery, can reduce the need for additional procedures or medications in adults with chronic sinusitis. About 300 participants will receive either the drug-coated balloon or a plain bal…
Phase: NA • Sponsor: Airiver Medical, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New mRNA vaccine combo aims to stop lung cancer recurrence
Disease control Recruiting nowThis Phase 3 trial tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (Keytruda) can prevent non-small cell lung cancer from coming back after surgery. About 868 people with stage II-IIIB lung cancer who have had their tumors completely removed wil…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug could keep lung cancer from coming back after surgery
Disease control Recruiting nowThis phase 3 trial tests whether the immunotherapy drug cemiplimab can prevent lung cancer from returning after surgery in patients with stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 levels of 1% or higher. About 390 participants will either receive cem…
Phase: PHASE3 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for EGFR lung cancer patients after targeted therapy fails
Disease control Recruiting nowThis study tests a new drug called izalontamab brengitecan against standard chemotherapy in 500 people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer) that has stopped responding to current targeted pills. The goal is to see if the new drug can delay…
Phase: PHASE2, PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New enzyme shot takes aim at Hard-to-Treat tumors
Disease control Recruiting nowThis trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…
Phase: PHASE1, PHASE2 • Sponsor: Onchilles Pharma Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New Antibody-Drug conjugate enters human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…
Phase: PHASE1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for tough lung cancer: tarlatamab trial opens
Disease control Recruiting nowThis study tests a drug called tarlatamab in people with advanced small cell lung cancer that has worsened after one prior treatment. About 48 participants will receive the drug by IV to see if it helps them live longer. The goal is to find a new option for patients who have limi…
Phase: PHASE2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for KRAS lung cancer: targeted combo enters phase 3 trial
Disease control Recruiting nowThis phase 3 trial tests whether adding the targeted drug adagrasib to standard immunotherapy and chemotherapy can help people with a specific genetic subtype of advanced lung cancer (KRAS G12C mutation) live longer without their cancer growing. About 630 adults who have not had …
Phase: PHASE3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug targets Hard-to-Treat cancers with KRAS mutation
Disease control Recruiting nowThis early-stage study is testing a new drug called calderasib (MK-1084) in people with advanced solid tumors that have a specific KRAS G12C mutation. The drug is given alone or combined with other cancer treatments. The main goals are to check safety and find the right dose. Abo…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could waiting on antibiotics be better for kids with CF?
Disease control Recruiting nowThis study looks at two ways to treat lung flare-ups in children with cystic fibrosis. One group starts antibiotics right away, while the other only takes them if symptoms don't improve. Researchers will track lung function over a year to see which approach works better. The goal…
Phase: NA • Sponsor: University of Washington, the Collaborative Health Studies Coordinating Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered virus plus immunotherapy aims to outperform chemo in advanced lung cancer
Disease control Recruiting nowThis phase 3 trial tests whether a combination of an injected virus therapy (CAN-2409) and an immunotherapy drug (pembrolizumab) can help people with stage IV non-squamous non-small cell lung cancer live longer than standard chemotherapy. The virus is designed to kill tumor cells…
Phase: PHASE3 • Sponsor: Candel Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New implant aims to silence snoring and save lives
Disease control Recruiting nowThis study is testing a device called the Genio® System for people with moderate to severe obstructive sleep apnea who cannot use CPAP machines. The device is implanted and stimulates the tongue to keep the airway open during sleep. Researchers will track how well it reduces brea…
Sponsor: Nyxoah Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could a simple nasal device replace ventilators for COPD emergencies?
Disease control Recruiting nowThis study compares a nasal high-flow device to standard non-invasive ventilation (NIV) for treating people who come to the emergency room with a severe COPD flare-up and high carbon dioxide levels. Participants are randomly assigned to receive one of the two breathing supports f…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for STK11 lung cancer: experimental combo enters trial
Disease control Recruiting nowThis phase II trial tests whether adding an experimental antibody called GT103 to the immunotherapy drug pembrolizumab can help people with advanced STK11-mutant non-small cell lung cancer. The study enrolls 28 adults whose cancer has worsened despite prior pembrolizumab treatmen…
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug XB010 takes on advanced cancers in first human trial
Disease control Recruiting nowThis early study tests an experimental drug called XB010, alone or combined with the immunotherapy pembrolizumab, in people with advanced solid tumors (like lung, breast, or head and neck cancers) that have stopped responding to other treatments. The main goals are to find a safe…
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New antibody WIN378 aims to tame COPD lung inflammation
Disease control Recruiting nowThis phase 2 trial is testing a new medicine called WIN378 for people with moderate to severe COPD. WIN378 is a long-acting antibody that blocks a protein involved in lung inflammation. The study will test different doses in 105 adults who are former smokers and already on standa…
Phase: PHASE2 • Sponsor: Windward Bio • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…
Phase: PHASE1 • Sponsor: Hangzhou DAC Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New antiviral pill aims to shorten RSV symptoms in vulnerable adults
Disease control Recruiting nowThis study tests an oral antiviral called ziresovir (AK0529) in adults at high risk for severe RSV infection, such as those with chronic lung or heart disease, weakened immune systems, or age 65 and older. Participants receive either the drug or a placebo, and researchers measure…
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New lupus drug candidate enters first human tests
Disease control Recruiting nowThis early-stage trial is testing a new drug called GSK4527363 in healthy volunteers and people with active lupus or lupus-related lung disease. The main goal is to check safety and how the body handles the drug. Around 142 participants will take part across four groups, includin…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Radioactive drug takes on standard therapy in lung cancer trial
Disease control Recruiting nowThis phase II trial tests whether a radioactive drug called lutetium Lu 177 dotatate works better than the usual drug everolimus for people with advanced bronchial neuroendocrine tumors (a type of lung cancer). The radioactive drug targets a protein on tumor cells and delivers ra…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a simple fat supplement protect preemie lungs?
Disease control Recruiting nowThis trial investigates whether giving very preterm infants (born at 24-29 weeks) a daily supplement of two fatty acids—ARA and DHA—starting within three days of birth can reduce their risk of bronchopulmonary dysplasia (BPD), a chronic lung disease common in premature babies. Ha…
Phase: PHASE4 • Sponsor: Aristotle University Of Thessaloniki • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets tough cancers with KRAS G12D mutation
Disease control Recruiting nowThis early-phase study tests a new drug, LY3962673, in people with advanced solid tumors that have a specific KRAS G12D mutation, including pancreatic, lung, and colorectal cancers. The main goals are to check safety and see if the drug shrinks tumors, given alone or with chemoth…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to boost immune attack on lung cancer
Disease control Recruiting nowThis phase 2 trial tests whether combining two drugs, SX-682 and pembrolizumab, can shrink tumors in people with advanced non-small cell lung cancer that has spread or come back. The study will enroll 30 adults whose tumors have a certain protein (PD-L1) and who have not had prio…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a drug combo shield lungs from radiation damage?
Disease control Recruiting nowThis study tests whether taking pentoxifylline and vitamin E during chemoradiation can prevent lung injury (pneumonitis) in stage III non-small cell lung cancer patients. 150 participants will receive either the drug combo or a placebo for 6 months. The goal is to see if this red…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough lung cancer: targeted drug cocktails enter human testing
Disease control Recruiting nowThis study tests a new targeted therapy called MK-1084, alone or combined with other drugs, in 190 people with advanced non-squamous non-small cell lung cancer that has a specific KRAS G12C mutation and has worsened after prior treatments. The main goals are to check safety and s…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Nanoparticles boost radiation against tough brain tumors
Disease control Recruiting nowThis study tests whether adding AGuIX gadolinium-based nanoparticles to standard brain radiation can better control brain metastases that are at high risk of coming back. About 134 adults with certain cancers (like melanoma, lung, breast, or colorectal) that have spread to the br…
Phase: PHASE2 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Phone therapy boosts inhaler use in anxious asthma patients
Disease control Recruiting nowThis study tests whether weekly phone calls with education, relaxation techniques, and motivational interviewing can help adults with asthma who are anxious about using their inhalers. 216 participants will be split into two groups: one gets the extra phone support, the other get…
Phase: NA • Sponsor: First Affiliated Hospital of Ningbo University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill targets Hard-to-Treat cancers: early trial recruits 554 patients
Disease control Recruiting nowThis study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for advanced lung cancer: drug cocktails under trial
Disease control Recruiting nowThis study tests new combinations of cancer drugs in people with advanced or metastatic non-small cell lung cancer. The goal is to find safer and more effective treatments. About 152 participants will receive either novel drug pairs or new drugs plus standard therapy. The study f…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation boost may tame brain spread in lung cancer
Disease control Recruiting nowThis study is for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has spread to the brain. Researchers want to see if adding a precise, one-time radiation treatment (SRS) to the standard drug osimertinib is better than the drug alone at controlling brain tumor…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Inhaled treprostinil aims to slow lung decline in fibrosis trial
Disease control Recruiting nowThis phase 3 study tests whether an inhaled drug called treprostinil can slow the worsening of lung function in people with progressive pulmonary fibrosis, a condition where lung scarring gets worse over time. About 698 adults will receive either the drug or a placebo four times …
Phase: PHASE3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to tackle tough lung cancer mutation
Disease control Recruiting nowThis Phase 3 study tests whether adding olomorasib (a targeted pill) to standard immunotherapy (pembrolizumab or durvalumab) works better than immunotherapy alone for people with KRAS G12C-mutant non-small cell lung cancer. The trial has two parts: one for patients whose cancer w…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New shot could reduce COPD Flare-Ups
Disease control Recruiting nowThis study tests an experimental drug called PF-07275315 in adults with moderate-to-severe COPD who have had at least two flare-ups in the past year. Participants receive either the drug or a placebo as injections over several months. The goal is to see if the drug improves lung …
Phase: PHASE2, PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to personalize lung cancer treatment
Disease control Recruiting nowThis study is for people with a specific type of advanced lung cancer (EGFR L858R mutation). It tests a treatment plan that starts with a targeted drug (aumolertinib) alone for 6 weeks, then adds chemotherapy for 4 cycles, and finally continues with the targeted drug alone. The g…
Phase: PHASE2 • Sponsor: Taipei Medical University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to shield cancer patients from chemo side effects
Disease control Recruiting nowThis study tests if trilaciclib can protect bone marrow in people with limited-stage small cell lung cancer receiving chemotherapy. About 120 participants will get either trilaciclib or a placebo. The goal is to reduce severe low white blood cell counts and other complications fr…
Phase: PHASE3 • Sponsor: Pharmacosmos A/S • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radioactive drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new radioactive drug (177Lu-DFC413) to see if it is safe and can shrink tumors in people with advanced solid cancers like pancreatic, lung, breast, colorectal, and sarcoma. About 180 adults whose cancer has progressed after standard treatments …
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to shrink hard-to-treat cancers
Disease control Recruiting nowThis study tests whether combining two drugs, YL201 and ivonescimab, can safely shrink tumors in people with advanced solid cancers, including lung cancer. About 260 adults whose cancer has not responded to other treatments will receive the combination. The goal is to find the be…
Phase: PHASE1, PHASE2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could less radiation be safer for tough lung tumors?
Disease control Recruiting nowThis study tests a lower-dose radiation regimen for people with non-small cell lung cancer located near the center of the chest. The goal is to see if giving a total of 45 Gray in three sessions can control the tumor while reducing damage to nearby organs like the heart and major…
Phase: PHASE1, PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Double-Drug attack targets tough lung cancer
Disease control Recruiting nowThis trial investigates whether combining two targeted drugs, vebreltinib and furmonertinib, can control advanced non-small cell lung cancer in people whose tumors have both an EGFR mutation and high PD-L1 expression. The study enrolls about 45 adults who have not received prior …
Phase: PHASE1, PHASE2 • Sponsor: Second Affiliated Hospital of Nanchang University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Womb balloon may boost lung growth in severe birth defect
Disease control Recruiting nowThis trial tests a procedure called FETO, where a small balloon is placed in the windpipe of a fetus with severe left congenital diaphragmatic hernia (CDH). The balloon blocks the airway temporarily, which may help the lungs grow larger before birth. The study includes pregnant w…
Phase: NA • Sponsor: Connecticut Children's Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Exercise boosts asthma control in severe cases, trial investigates
Disease control Recruiting nowThis trial tests whether a 6-month personalized exercise program improves exercise capacity and asthma control in adults with severe asthma who are starting biologic therapy. Participants are randomly assigned to either the exercise program or standard advice to increase physical…
Phase: NA • Sponsor: Helsinki University Central Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy duo aims to boost lung cancer cure rates before surgery
Disease control Recruiting nowThis phase 2 trial is testing whether adding two immunotherapy drugs, IPH5201 and durvalumab, to standard chemotherapy before and after surgery can improve outcomes for people with early-stage (stage II to III) non-small cell lung cancer. The study includes two groups: one receiv…
Phase: PHASE2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a watchful software save ICU patients from organ failure?
Disease control Recruiting nowThis trial tests whether a special alert system called ICU Beacon can help doctors in intensive care units detect early signs of organ failure. The study includes about 1,962 adult ICU patients and compares units using the software plus standard care to those using standard care …
Sponsor: ETH Zurich • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a gentler chemo combo with delayed immunotherapy tame advanced lung cancer?
Disease control Recruiting nowThis study investigates whether a lower dose of two chemotherapy drugs (carboplatin and nab-paclitaxel) combined with a delayed dose of the immunotherapy serplulimab can effectively treat advanced squamous non-small cell lung cancer. The trial compares this gentler regimen to a s…
Phase: EARLY_PHASE1 • Sponsor: People's Hospital of Quzhou • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Drug combo aims to halt lung scarring in scleroderma
Disease control Recruiting nowThis trial tests whether adding rituximab to standard mycophenolate mofetil (MMF) therapy can improve lung function in people with severe lung scarring caused by systemic sclerosis. About 102 adults with this condition will receive either rituximab infusions plus MMF or placebo i…
Phase: PHASE3 • Sponsor: University Hospital, Tours • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New pill targets Hard-to-Treat cancers with a specific gene mutation
Disease control Recruiting nowThis study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New score could help doctors spot fungal pneumonia faster
Diagnosis Recruiting nowThis study aims to create and test a clinical prediction score called FUNGAL-P to help doctors identify fungal pneumonia early in adults who come to the hospital with pneumonia. Researchers will analyze medical records from past patients and then test the score on new patients to…
Sponsor: Azienda Ospedaliero-Universitaria Careggi • Aim: Diagnosis
Last updated Jul 03, 2026 23:00 UTC
-
AI reads your heartbeat to catch silent killer in lung patients
Diagnosis Recruiting nowThis study tests whether an artificial intelligence (AI) tool that analyzes a simple ECG can help doctors find undiagnosed pulmonary hypertension (high blood pressure in the lungs) in people with interstitial lung disease. About 900 adults with severe lung scarring will be random…
Phase: NA • Sponsor: Tempus AI • Aim: Diagnosis
Last updated Jul 03, 2026 23:00 UTC
-
Could a Pocket-Sized spirometer replace hospital lung tests?
Diagnosis Recruiting nowThis study will test a handheld ultrasonic spirometer against a conventional hospital spirometer in 100 adults with chronic respiratory diseases like COPD or asthma. Each participant will use both devices to see if the portable one gives accurate and reliable results. If successf…
Phase: NA • Sponsor: Fu Jen Catholic University • Aim: Diagnosis
Last updated Jul 03, 2026 23:00 UTC
-
Ultrasound may help doctors time lifesaving lung treatment for preterm infants
Diagnosis Recruiting nowThis study tests whether using a lung ultrasound score can help doctors decide when to give surfactant therapy to premature infants with respiratory distress syndrome. Surfactant is a substance that helps babies' lungs stay open, but giving it too late can reduce its benefit. The…
Phase: NA • Sponsor: Connecticut Children's Medical Center • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
AI-Powered blood test could spot five cancers before symptoms show
Diagnosis Recruiting nowThis study is testing a new blood test called EXoPred that uses artificial intelligence and laser technology to find tiny particles from cancer cells. The goal is to detect breast, colon, pancreatic, ovarian, and lung cancers at an early stage. Researchers will enroll 1,400 peopl…
Sponsor: EXoPERT • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
Could a simple questionnaire replace sleep lab tests for kids?
Diagnosis Recruiting nowThis study aims to see if a French version of the OSA-18 questionnaire can accurately identify obstructive sleep apnea in children. Parents of children aged 4 to 17 who are already scheduled for a sleep test (polysomnography) will fill out the questionnaire. The results will be c…
Sponsor: Hospices Civils de Lyon • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New PET scan targets hidden lung cancer cells
Diagnosis Recruiting nowThis study tests a new type of PET/CT scan that looks for a protein called DLL3 on small cell lung cancer cells. The goal is to see if this scan can find tumors more clearly than standard imaging methods like CT or regular PET scans. About 20 adults with suspected or confirmed sm…
Phase: NA • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New blood test could spot 10 cancers before symptoms start
Diagnosis Recruiting nowThis study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New AI-Powered swab test aims to spot viruses in minutes
Diagnosis Recruiting nowThis study tests a new technology called Pictura Bio that aims to detect respiratory viruses quickly and cheaply from nose or throat swabs. Researchers will collect samples from 1000 adults and children with suspected viral infections at a UK hospital. The data will be used to tr…
Sponsor: Portsmouth Hospitals NHS Trust • Aim: Diagnosis
Last updated Jul 02, 2026 00:00 UTC
-
New rapid tests for respiratory infections put to the test in africa
Diagnosis Recruiting nowThis study is testing new rapid tests (lateral flow and microfluidic devices) to detect respiratory infections in children and adults in Uganda, Ethiopia, and Senegal. Researchers want to see if these tests are accurate and easy to use in low-resource clinics. Participants with r…
Sponsor: Karolinska Institutet • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
New PET tracers aim to light up Hard-to-See cancers
Diagnosis Recruiting nowThis early-phase study is testing two radioactive imaging agents, 68Ga-DFC413 and 68Ga-NNS309, to see how well they highlight tumors on PET scans. About 66 adults with advanced pancreatic, lung, breast, colorectal, or soft tissue cancers will receive the agents. The goal is to co…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New PET scan tracer could light up hidden lung cancers
Diagnosis Recruiting nowThis study tests a new radioactive tracer called 89Zr-DFO-SC16.56 that attaches to a protein called DLL3 found on small cell lung cancer cells. The goal is to see if PET scans using this tracer can safely and accurately show where the cancer is in the body. About 53 adults with s…
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
New wearable could make sleep apnea diagnosis easier for kids
Diagnosis Recruiting nowThis study is testing a wearable sensor that measures oxygen levels in the brain and limbs of children with and without obstructive sleep apnea (OSA). The sensor, called near-infrared spectroscopy (NIRS), is compared to standard sleep study techniques. Researchers hope it could l…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
New portable device could speed up asthma diagnosis
Diagnosis Recruiting nowThis study aims to see if a portable device that measures lung function can accurately diagnose asthma in people with symptoms like wheezing or coughing. Researchers will compare this new test to the standard breathing tests currently used. The study plans to enroll 500 adults ac…
Phase: NA • Sponsor: AstraZeneca • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
Breath sniffing test could spot lung trouble in ventilator patients
Diagnosis Recruiting nowThis study is testing a new way to check the health of ICU patients who are on breathing machines. Researchers collect a small sample of the air patients breathe out and analyze its proteins. They also take a blood sample to look for related changes in DNA, RNA, and other molecul…
Sponsor: The Institute of Molecular and Translational Medicine, Czech Republic • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
New radioactive tracer could spot lung cancer mutations
Diagnosis Recruiting nowThis early-stage trial tests a radioactive imaging agent called [111In]-FPI-2107 in 12 Chinese adults with EGFR-mutant non-small cell lung cancer. The goal is to see if it is safe and can help detect tumors on SPECT scans. Participants receive the agent plus an unlabelled antibod…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Could your phone diagnose sleep apnea? new trial tests app in cancer patients
Diagnosis Recruiting nowThis study tests whether a smartphone app called Apneal can help screen for obstructive sleep apnea in people with head and neck cancer. Sleep apnea is common but often missed in these patients, and current diagnosis requires expensive equipment. Participants use the app at home …
Phase: NA • Sponsor: University Hospital, Caen • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
AI-Powered screening aims to catch lung cancer early in veterans
Prevention Recruiting nowLung cancer is the top cancer killer of Veterans, often found too late to cure. This trial tests whether giving doctors personalized prediction tools and dashboards can increase lung cancer screening rates among 23,520 high-risk Veterans. The goal is to catch cancer earlier and r…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Prevention
Last updated Jun 28, 2026 00:00 UTC
-
Hope for High-Risk families: drug aims to stop lung scarring before it starts
Prevention Recruiting nowThis study tests a drug called nerandomilast in 80 people aged 40+ who have early lung changes and a family history of pulmonary fibrosis. Participants take either the drug or a placebo twice daily for up to 3 years. Doctors monitor lung function and scans to see if the drug slow…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
New asthma drug enters early human safety testing
Symptom relief Recruiting nowThis early-stage study tests a single dose of an experimental drug called CDX-622 in 12 adults with mild to moderate asthma. The main goal is to see if the drug is safe and to measure how it affects markers of airway inflammation. Participants will be monitored for side effects a…
Phase: PHASE1 • Sponsor: Celldex Therapeutics • Aim: Symptom relief
Last updated Jul 03, 2026 23:00 UTC
-
Home workouts via video calls could ease cancer side effects
Symptom relief Recruiting nowThis study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…
Phase: NA • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief
Last updated Jul 03, 2026 23:00 UTC
-
New hope for better sleep after spinal injury
Symptom relief Recruiting nowThis study tests three approaches—oxygen therapy, the drug trazodone, and brief low-oxygen episodes—to see if they can improve sleep apnea in people with chronic cervical spinal cord injury. Researchers will measure changes in breathing and sleep quality in 100 participants. The …
Phase: PHASE4 • Sponsor: John D. Dingell VA Medical Center • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Yoga and mindfulness may help cancer survivors heal from within
Symptom relief Recruiting nowThis study tests whether yoga and mindfulness programs can improve quality of life, reduce inflammation, and even affect gene activity in people who have survived lung, colon, or non-Hodgkin's lymphoma cancer. One hundred survivors, at least six months past treatment, will be ran…
Phase: NA • Sponsor: Barbara Nemesure • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Beetroot juice may boost exercise in lung scarring disease
Symptom relief Recruiting nowThis study investigates whether drinking nitrate-rich beetroot juice twice a day for three days can improve exercise capacity in people with idiopathic pulmonary fibrosis (IPF), a lung scarring disease that limits activity. Researchers will compare the juice to a placebo in a sma…
Phase: NA • Sponsor: University Hospital Southampton NHS Foundation Trust • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Can a Pre-Procedure painkiller ease the pain of lung nodule marking?
Symptom relief Recruiting nowThis trial tests whether giving the painkiller parecoxib before a CT-guided wire placement can reduce pain during lung nodule localization for surgery. About 150 adults with lung cancer scheduled for video-assisted thoracoscopic surgery will receive either parecoxib or a placebo …
Phase: PHASE4 • Sponsor: Long Jiang • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
New drug raphamin aims to shorten bronchitis suffering
Symptom relief Recruiting nowThis Phase 3 trial tests whether the drug Raphamin can help adults with acute bronchitis recover faster. About 308 participants will take either Raphamin or a placebo for 5 days. Researchers will track symptoms like cough and chest pain to see if Raphamin reduces illness duration…
Phase: PHASE3 • Sponsor: Materia Medica Holding • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Can steroids reverse nerve damage from cancer radiation?
Symptom relief Recruiting nowThis study tests high-dose steroids (methylprednisolone or prednisone) in 35 head and neck cancer survivors who have nerve damage from past radiation. The goal is to find the best dose that improves symptoms like tongue weakness while limiting side effects. Participants must be a…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Freezing nerves during lung surgery may cut opioid use
Symptom relief Recruiting nowThis study tests whether freezing certain nerves during minimally invasive lung surgery can help patients recover faster with less pain. 150 adults having lung surgery will either get standard pain management or standard care plus nerve freezing. The goal is to see if the freezin…
Phase: NA • Sponsor: St. Antonius Hospital • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Lung rehab gains fade? new study tests personalized coaching to keep patients moving
Symptom relief Recruiting nowThis study tests whether personalized follow-up with a sport-health professional helps people with chronic respiratory diseases maintain the benefits of pulmonary rehabilitation. 352 participants will either receive tailored support or usual care. The main goal is to see if those…
Phase: NA • Sponsor: University Hospital, Brest • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
New device aims to suck trapped air out of lungs in just 20 minutes
Symptom relief Recruiting nowThis study tests whether a single 20-minute session with a medical device called Simeox can reduce the amount of air trapped in the lungs of people with severe COPD. The device applies gentle suction during exhalation to help move air out. Researchers will measure lung function b…
Phase: NA • Sponsor: Azienda Socio Sanitaria Territoriale di Lodi • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
Sweat it out: exercise may supercharge lung cancer immunotherapy
Symptom relief Recruiting nowThis study tests whether a home-based aerobic exercise program can help lung cancer patients respond better to immunotherapy. Researchers will measure changes in immune cells and inflammation markers in 100 participants. The goal is to see if exercise can improve treatment effect…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
New inhaler aims to calm asthma Flare-Ups
Symptom relief Recruiting nowThis study tests an inhaled medication called ARO-RAGE in 36 adults with mild asthma that is triggered by allergens. The goal is to see if it improves small airway function after breathing in an allergen. Participants will receive either the drug or a placebo and be monitored for…
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
Could a piece of tape cure your snoring? new study tests the idea
Symptom relief Recruiting nowThis study tests whether a silicone mouth tape worn during sleep can reduce snoring and improve sleep quality in people with mild sleep apnea or simple snoring. About 100 adults with a bed partner will use the tape for a period, and both the snorer and partner will report on snor…
Phase: PHASE2 • Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Mouth spray could tame agonizing swallowing pain during cancer radiation
Symptom relief Recruiting nowThis clinical trial tests whether a doxepin solution spray can relieve severe breakthrough pain when swallowing, a common side effect of radiation therapy for nasopharyngeal carcinoma. About 178 patients will be randomly assigned to receive either the doxepin spray or a placebo s…
Phase: NA • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Asthma relief in a chew? plant stanols put to the test
Symptom relief Recruiting nowThis study is testing whether eating a soft chew containing plant stanols every day can reduce asthma symptoms in people with allergic asthma. Plant stanols are known to lower cholesterol, but they may also shift the immune system away from the type of response that triggers asth…
Phase: NA • Sponsor: Maastricht University Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
New app aims to keep young cystic fibrosis patients moving
Symptom relief Recruiting nowThis study tests a smartphone program called NUDGE that acts like a health coach for teens and young adults (ages 13-25) with cystic fibrosis. Participants set activity goals, track progress, and get feedback through the app. The goal is to see if the app helps them stay active a…
Phase: NA • Sponsor: Nemours Children's Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Cancer injection satisfaction study recruits 700 patients
Symptom relief Recruiting nowThis study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …
Sponsor: Hoffmann-La Roche • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Could a common drug fix sleep apnea and curb opioid cravings?
Symptom relief Recruiting nowThis study tests whether acetazolamide, a drug used for other types of sleep apnea, can help people on methadone or buprenorphine who develop central sleep apnea. Forty participants will take either the drug or a placebo for 7 days, then have an overnight sleep study. Researchers…
Phase: PHASE2 • Sponsor: Sanjay R Patel • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
New pill aims to shorten COPD Flare-Ups from common cold
Symptom relief Recruiting nowThis study tests an oral drug called vapendavir in 180 adults with COPD who catch a rhinovirus (common cold). The goal is to see if it can reduce the severity and length of breathing symptoms compared to a placebo. Participants are randomly assigned to one of two doses or a place…
Phase: PHASE2 • Sponsor: Altesa Biosciences, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
New drug aims to ease painful mouth sores for head and neck cancer patients
Symptom relief Recruiting nowThis phase II trial tests whether adding BMX-001 to standard symptom management can reduce severe mouth sores in head and neck cancer patients receiving chemoradiation. About 98 participants will receive either BMX-001 or a placebo alongside usual care. The goal is to see if BMX-…
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
New inhaled asthma drug begins first human safety trial
Symptom relief Recruiting nowThis early-stage trial tests a single inhaled dose of ASY202, a drug containing dihydroergotamine, in 40 adults with stable asthma. The study is randomized and placebo-controlled, meaning some participants get the drug and some get an inactive powder. The main goal is to check sa…
Phase: PHASE1 • Sponsor: Aspeya, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Arm and leg workout combo may ease daily struggles for COPD patients
Symptom relief Recruiting nowThis study tests whether combining arm and leg endurance training is better than leg training alone for improving daily activities in people with COPD. 36 participants with moderate-to-severe COPD will undergo 14 supervised sessions. The main goal is to see if the combined traini…
Phase: NA • Sponsor: Istituti Clinici Scientifici Maugeri SpA • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Smart oxygen machine could ease breathing for COPD patients
Symptom relief Recruiting nowThis study tests whether a device called Airvo 3, which automatically adjusts oxygen levels, can keep COPD patients' blood oxygen in a healthy range better than manual adjustments by nurses. About 70 hospitalized adults with COPD and low oxygen will take part. The goal is to see …
Phase: NA • Sponsor: Fisher and Paykel Healthcare • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Needles before knife: acupuncture may ease Post-Surgery sleep problems
Symptom relief Recruiting nowThis study tests whether acupuncture at specific points before and after lung cancer surgery can improve sleep and reduce long-term pain. About 316 patients will receive either real or sham acupuncture alongside standard care. The goal is to see if this simple, low-risk treatment…
Phase: NA • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Can a simple nasal device boost exercise in COPD patients?
Symptom relief Recruiting nowThis study looks at whether using a nasal high-flow device (which delivers warm, moist air at a high rate) can help people with COPD walk farther during a 6-minute walk test. Thirty adults with COPD will try both the high-flow device and a standard low-flow device on different da…
Phase: NA • Sponsor: University of Miami • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Can a Culturally-Tailored therapy reduce anxiety in advanced cancer patients?
Symptom relief Recruiting nowThis study tests whether a therapy called Meaning-Centered Psychotherapy for Latinos (MCP-L) can help reduce anxiety and depression in 300 Latino patients with advanced cancer. Participants receive either MCP-L or standard cognitive behavioral therapy over about 3 months. The goa…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
New anxiety program for ICU survivors shows promise in early trial
Symptom relief Recruiting nowThis pilot study tests a self-management program based on cognitive behavioral therapy to help people who survived acute respiratory failure and now struggle with anxiety. Sixty ICU survivors will either receive the program or usual care. The goal is to see if the program is prac…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
New drug could ease constant allergy symptoms
Symptom relief Recruiting nowThis phase 3 study tests lebrikizumab, an injectable drug, in 450 adults with perennial allergic rhinitis (year-round allergies). The goal is to see if it reduces nasal symptoms like congestion and sneezing compared to a placebo. Participants will be followed for up to 29.5 month…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Can sexology consultations restore intimacy after throat cancer surgery?
Symptom relief Recruiting nowThis study tests whether a series of sexology consultations can help people who had their voice box removed due to throat cancer, along with their partners, feel better about their intimate lives. The program involves individual talks with a trained sexology nurse and questionnai…
Sponsor: Institut Claudius Regaud • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Scientists seek answers for rare immune disorder
Knowledge-focused Recruiting nowThis study aims to learn more about Hyper IgE syndrome, a rare immune disorder that causes skin and lung infections. Researchers will follow 600 patients and their relatives over time, examining their health and genetics. The goal is to better understand the disease and improve c…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Scientists seek clues on white blood cell behavior in allergies and parasites
Knowledge-focused Recruiting nowThis study aims to understand how and why eosinophils (a type of white blood cell) become active in conditions like allergies, asthma, and parasitic infections. Researchers will observe up to 800 people aged 1 to 100 with high eosinophil levels. No experimental treatments are giv…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
2000 volunteers help create a gold standard for cancer blood tests
Knowledge-focused Recruiting nowThis study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
NIH launches Long-Term study to uncover clues in rare lung disease
Knowledge-focused Recruiting nowThis natural history study follows 270 adults with pulmonary arterial hypertension (PAH) and healthy volunteers to track how the disease changes over time. Researchers will use blood tests, heart and lung imaging, and a six-minute walk test to find new markers of disease severity…
Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Breathing new life into lung monitoring: MRI with inhaled gas tracks cystic fibrosis
Knowledge-focused Recruiting nowThis study tests a new MRI method that uses an inhaled gas to create detailed images of lung ventilation in people with cystic fibrosis. Researchers will track 30 adults with mild lung disease over a year, comparing the MRI results to standard breathing tests. The goal is to see …
Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Could a mediterranean diet help kids with cystic fibrosis?
Knowledge-focused Recruiting nowThis study looks at whether a Mediterranean diet can improve gut health in children with cystic fibrosis. Twenty kids aged 3 and older will follow this diet for 6 months. Researchers will check changes in gut bacteria and inflammation markers. The goal is to offer better diet adv…
Phase: NA • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Taiwan launches genetic mapping study for throat cancer
Knowledge-focused Recruiting nowThis study aims to collect and analyze genetic information from 300 Taiwanese patients with oropharyngeal cancer. Researchers will use advanced DNA sequencing to find genetic changes linked to the disease. The goal is to improve understanding and help design future treatments or …
Sponsor: National Health Research Institutes, Taiwan • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Breath, blood, and saliva tests could replace sputum for CF lung infections
Knowledge-focused Recruiting nowThis study looks for better ways to find harmful bacteria in the lungs of people with cystic fibrosis. Traditional sputum tests are becoming harder to use because newer CF treatments reduce mucus. Researchers will collect samples like saliva, blood, urine, and breath from 300 par…
Sponsor: Chris Goss • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Scientists hunt for genetic clues in lung and esophageal cancers
Knowledge-focused Recruiting nowThis study aims to collect tumor, normal tissue, and blood samples from up to 1559 people with cancers of the lung, esophagus, or pleura. Researchers will analyze genetic and epigenetic changes to better understand these diseases and identify potential markers for future treatmen…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Researchers launch major tissue bank to unlock secrets of mesothelioma
Knowledge-focused Recruiting nowThis study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Scientists launch major study to track viruses in healthy and immunocompromised patients
Knowledge-focused Recruiting nowThis study aims to collect samples and medical information from people of all ages who have or have been exposed to viral infections, including COVID-19 and herpes. Researchers want to understand how viruses affect healthy individuals versus those with weakened immune systems. Pa…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
New study aims to cut diagnostic delays for lung scarring patients
Knowledge-focused Recruiting nowThis study tests whether bundling key tests like scans and lung function tests into a single, fast-tracked appointment can help people with suspected interstitial lung disease get a diagnosis sooner. About 92 adults will be randomly assigned to either the usual step-by-step testi…
Phase: NA • Sponsor: Hospital de Granollers • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Rare cancer syndrome under the microscope: what families need to know
Knowledge-focused Recruiting nowThis study follows people with a rare genetic condition called DICER1 syndrome, which raises the risk of certain childhood cancers like pleuropulmonary blastoma. Researchers will collect medical histories, genetic samples, and tissue from up to 1,500 participants and their relati…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
New monitoring methods could make home ventilation safer and more comfortable
Knowledge-focused Recruiting nowThis study aims to develop a better way to remotely monitor people with chronic respiratory failure who use a breathing machine (noninvasive ventilation) at home. Researchers will collect data from standard monitoring tools and new non-invasive devices to assess breathing, lung f…
Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Scientists seek hidden causes of chronic lung infections
Knowledge-focused Recruiting nowThis study follows 900 people with bronchiectasis—a condition where airways are damaged and prone to infection—to learn why they get sick repeatedly. Researchers will collect medical history, lung function tests, and blood, urine, and sputum samples from patients and their family…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Scientists launch deep dive into rare bleeding and lung disease
Knowledge-focused Recruiting nowThis study aims to learn more about Hermansky-Pudlak Syndrome (HPS), a rare inherited disease that causes light skin/eye color, bleeding problems, and often deadly lung scarring. Researchers will follow 600 people with HPS and their family members to track how the disease progres…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Can smell training rewire the brain and immune system?
Knowledge-focused Recruiting nowThis study looks at people with smell loss caused by chronic rhinosinusitis. Participants will undergo a 3-month smell training program. Researchers will measure changes in smell function, mental health, and immune markers in blood and tissue samples. The goal is to understand th…
Phase: NA • Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Sickle cell study aims to uncover disease patterns
Knowledge-focused Recruiting nowThis study follows up to 3,500 people with sickle cell disease to learn more about how the condition progresses and what complications arise. Participants receive their usual medical care outside the hospital and visit the clinic for check-ups and research tests. No experimental …
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
AI assistant could help ICU ventilator settings
Knowledge-focused Recruiting nowThis study tests a new AI system called IntelliLung that suggests ventilator settings for ICU patients on breathing machines. Researchers will compare how often doctors' settings match the AI's recommendations. About 530 adults on ventilators will take part across multiple hospit…
Sponsor: Technische Universität Dresden • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
New MRI gas test could spot early lung problems in kids with cystic fibrosis
Knowledge-focused Recruiting nowThis study explores a new type of MRI that uses an inhaled gas to create images of lung ventilation in children ages 6-17. Researchers will compare results between children with mild cystic fibrosis and healthy children to see if the technique is feasible and sensitive to early l…
Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Camera during sleep may reveal best surgery for apnea
Knowledge-focused Recruiting nowThis study investigates a technique called drug-induced sleep endoscopy (DISE) to examine the upper airway in adults with obstructive sleep apnea (OSA) who are considering surgery. Participants receive a mild sedative (propofol) to induce sleep, then a thin camera is passed throu…
Phase: PHASE2 • Sponsor: University of California, Los Angeles • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Scientists track asthma in urban kids to uncover hidden patterns
Knowledge-focused Recruiting nowThis study follows 310 children aged 6 to 17, some with asthma and some without, for one year. Researchers want to learn how different types of asthma cause symptoms and sudden attacks. Participants keep track of cold symptoms and attend regular check-ups. The goal is to better u…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New online tool aims to ease financial burden for cancer patients
Knowledge-focused Recruiting nowThis study is testing a web-based tool called CARE that gives cancer patients information about treatment costs, health insurance, and financial resources. About 430 adults with gynecologic, prostate, lung, or colorectal cancer will use the tool to see if it helps them feel more …
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Study aims to uncover gaps in emergency care for newborns with oxygen deprivation
Knowledge-focused Recruiting nowThis study looks at how well hospitals manage severe oxygen deprivation (asphyxia) in newborns at or near full term. Researchers will review care given during labor and after birth to find where improvements can be made. The goal is to help doctors and nurses provide better, fast…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New imaging reveals hidden lung blockages in severe asthma
Knowledge-focused Recruiting nowThis study looks at how mucus plugs in the lungs affect breathing in people with severe asthma. Researchers will use special MRI scans to see air flow in blocked areas. Only 5 adults with severe asthma will take part, and the goal is to better understand lung function, not to tes…
Sponsor: University of Kansas Medical Center • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Can tongue exercises unlock better sleep? new study investigates
Knowledge-focused Recruiting nowThis study looks at whether special mouth and throat exercises can improve sleep apnea by strengthening the muscles that keep the airway open. Thirty adults with sleep apnea will use myofunctional therapy devices for three months. Researchers will measure muscle pressure in the t…
Phase: NA • Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Mind over lungs: could mental health hold the key to preventing asthma attacks?
Knowledge-focused Recruiting nowThis study looks at whether anxiety or depression makes asthma harder to control and aims to build a model that predicts when a serious asthma attack might happen. Researchers will follow 256 people with asthma for up to two years, tracking their symptoms, mental health, and lung…
Sponsor: Xiangya Hospital of Central South University • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Scientists hunt for blood markers to unmask hidden aggressive tumors
Knowledge-focused Recruiting nowThis study collects blood and tumor tissue samples from people with head and neck or lung cancers to find biological markers that indicate low oxygen levels within tumors. Low-oxygen tumors tend to be more aggressive and resistant to standard treatments like radiation and chemoth…
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Healthy volunteers needed to help fight flu and zika
Knowledge-focused Recruiting nowThis study screens up to 5,000 healthy adults aged 18-65 to see if they can join future research on infectious diseases like flu and Zika. Volunteers undergo a 3-5 hour checkup including blood tests, heart exam, and chest X-ray. The goal is to build a pool of eligible participant…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
New study aims to fine-tune breathing support for critically ill children
Knowledge-focused Recruiting nowThis study looks at 50 children (over 1 year old) in intensive care who are on breathing machines due to acute respiratory distress syndrome (ARDS). Researchers want to see if two methods can reliably measure airway opening pressure, which could help doctors personalize ventilati…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Massive study seeks to unlock how your surroundings and DNA shape disease risk
Knowledge-focused Recruiting nowThis study looks at how your genes and your environment—like what you eat, breathe, and experience—work together to influence common diseases such as diabetes, heart disease, and asthma. Researchers are collecting health questionnaires, genetic data, and other information from 25…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
New study aims to predict immunotherapy response in lung cancer patients before surgery
Knowledge-focused Recruiting nowThis study is looking for genetic clues that might tell doctors whether immunotherapy will work well before lung cancer surgery. Researchers will collect blood and tumor samples from 100 people with stage II-IIIB non-small cell lung cancer. They will test for two types of genetic…
Sponsor: Geneplus-Beijing Co. Ltd. • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Tiny tube reveals how much oxygen really reaches preterm lungs
Knowledge-focused Recruiting nowThis study looks at preterm infants who need breathing support from a machine called nasal CPAP. Researchers want to find out how much oxygen actually reaches the baby's lungs by placing a small tube in the back of the mouth and using soft bands around the chest to measure lung e…
Phase: NA • Sponsor: University of Arkansas • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Scientists collect tissue to unlock lung cancer secrets
Knowledge-focused Recruiting nowThis study collects tissue samples and health information from 2000 adults with certain lung and thymic cancers. Researchers aim to better understand these diseases, which could lead to new diagnostic tools and treatments. Participants provide blood, tumor samples, and imaging da…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Robotic lung biopsy system under Real-World scrutiny
Knowledge-focused Recruiting nowThis study is observing how well the Ion endoluminal system, a robotic tool, works for lung nodule biopsies and localization in everyday medical practice across Europe. Researchers will track 1,200 adults to see how often the tool correctly diagnoses lung nodules and how often co…
Sponsor: Intuitive Surgical • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Video link to doctor may boost paramedic safety for kids in crisis
Knowledge-focused Recruiting nowThis study tests whether a live video connection between paramedics and pediatric emergency doctors improves care for critically ill children. Paramedics will treat infant mannequins in simulated ambulance scenarios, with some getting video support and others only audio. The goal…
Phase: NA • Sponsor: Boston Medical Center • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can a simple blood test predict leukemia risk after cancer therapy?
Knowledge-focused Recruiting nowThis study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Scientists launch major study to unravel salivary gland mysteries
Knowledge-focused Recruiting nowThis study aims to learn more about diseases that affect the salivary glands, which produce saliva. Researchers will collect medical data, blood, saliva, and tissue samples from people with these conditions, their relatives, and healthy volunteers. The goal is to better understan…
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Scientists hunt for genes that protect the lungs
Knowledge-focused Recruiting nowThis study aims to find the genes that keep airways healthy and understand how genetic mutations cause primary ciliary dyskinesia (PCD), a rare disease that leads to serious lung problems. Researchers will study people with suspected PCD and healthy family members. The goal is to…
Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Sleep apnea study aims to predict heart trouble with better breathing metrics
Knowledge-focused Recruiting nowThis study will test new methods to measure how sleep apnea affects the heart. Researchers will follow 270 adults with moderate to severe sleep apnea who use CPAP, mouth devices, or nerve stimulation. The goal is to see if these new metrics can better predict heart problems than …
Sponsor: University Hospital, Antwerp • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Blood test may guide cancer care without biopsy
Knowledge-focused Recruiting nowThis study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovar…
Phase: NA • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Massive cancer database aims to unlock secrets of the disease
Knowledge-focused Recruiting nowThis study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…
Sponsor: University of Nebraska • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Live biopsy study aims to predict immunotherapy response in cancer patients
Knowledge-focused Recruiting nowThis study is collecting live tumor samples from 2,000 cancer patients undergoing standard biopsies. Researchers will analyze these samples to understand how tumors respond to immunotherapy drugs outside the body. The goal is to develop a method to predict which patients will res…
Sponsor: Elephas • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Could zapping two neck nerves cure sleep apnea?
Knowledge-focused Recruiting nowThis study looks at whether stimulating two nerves in the neck (the ansa cervicalis and hypoglossal nerve) can help people with obstructive sleep apnea. Researchers will measure how the airway changes during sleep in 100 adults. The goal is to understand if combining these stimul…
Phase: NA • Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Real-World check: Osimertinib's performance in spanish lung cancer patients under the microscope
Knowledge-focused Recruiting nowThis study observes 500 Spanish patients with EGFR-mutated non-small cell lung cancer who are taking osimertinib in routine care. It aims to measure survival, quality of life, and how long patients stay on treatment. The goal is to see if results from clinical trials hold up in r…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New study aims to predict which ICU patients need breathing tubes again
Knowledge-focused Recruiting nowThis study observes 600 adult patients after major surgery to see if simple bedside tests—like ultrasound of breathing muscles and a breathing score—can predict who will need a breathing tube again. No new treatments are given; doctors make all decisions as usual. The goal is to …
Sponsor: Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New imaging combo could sharpen lung cancer radiation
Knowledge-focused Recruiting nowThis study tests whether combining 4D MRI and 4D CT scans can better track lung tumors and nearby organs as a person breathes during radiation therapy. Researchers will compare this new method to the current standard. The goal is to see if it improves targeting of the tumor while…
Phase: NA • Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Oxygen trick during lung surgery may cut inflammation
Knowledge-focused Recruiting nowThis study tests whether giving oxygen to the lung that is not being ventilated during lung cancer surgery can reduce inflammation and improve oxygen levels. Researchers will measure inflammatory markers in lung tissue and blood from 56 adult patients. The goal is to see if this …
Phase: NA • Sponsor: Osijek University Hospital • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
10-Minute checkup could transform care for older lung cancer patients
Knowledge-focused Recruiting nowThis study tests a short, 10-15 minute health assessment called the Practical Geriatric Assessment (PGA) for adults aged 65 and older with early-stage non-small cell lung cancer who are about to receive radiation therapy. The goal is to see if using this quick checkup leads to mo…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New registry aims to map treatment landscape for rare lung cancer mutation
Knowledge-focused Recruiting nowThis study is a disease registry that will follow about 700 people with advanced non-small cell lung cancer that has a specific genetic change called METex14 skipping. Researchers will collect information on patient characteristics, treatments, and outcomes over time to better un…
Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New study aims to protect cancer Patients' hearts during radiation
Knowledge-focused Recruiting nowThis study watches for heart changes in 150 adults receiving chest radiation for lung, esophageal, breast, or thymus cancer. Researchers will check heart markers, electrical activity, and immune cells at the end of treatment and up to 3 months later. The goal is to find early sig…
Sponsor: Hebei Medical University Fourth Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Lung cancer drug under the microscope: how does cemiplimab perform in real life?
Knowledge-focused Recruiting nowThis study follows 500 European patients with advanced non-small cell lung cancer who are already prescribed cemiplimab (Libtayo) as part of their normal care. Researchers will track how long patients live, how well the cancer responds, and any side effects. The goal is to see if…
Sponsor: Regeneron Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Can a conversation aid empower lung cancer patients?
Knowledge-focused Recruiting nowThis study tests a low-literacy conversation tool designed to help lung cancer patients and their doctors make treatment decisions together. Researchers will enroll 300 patients to see if the tool improves understanding, reduces confusion, and boosts confidence in choices. The fo…
Phase: NA • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Lung cancer drug matching: lab test could personalize treatment
Knowledge-focused Recruiting nowThis study looks at whether testing lung cancer cells in a lab can predict which drugs will work best for each patient. Researchers will collect fluid from around the lungs of 400 people with lung cancer who need drainage for shortness of breath. They will grow the cancer cells i…
Sponsor: Sheba Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
AI could predict who lives longer after lung cancer immunotherapy
Knowledge-focused Recruiting nowThis study looks back at 600 advanced lung cancer patients who received immunotherapy. Researchers will analyze their tissue samples and genetic data to find patterns linked to long-term survival. They aim to build an AI model that can predict survival from standard microscope im…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Can understanding health info help COPD patients live better?
Knowledge-focused Recruiting nowThis study looks at how well people with COPD understand health information and how that relates to their physical abilities, thinking skills, daily activities, and quality of life. Researchers will compare 144 adults with COPD to healthy volunteers using tests of walking, thinki…
Sponsor: Hacettepe University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study tests if low oxygen makes heat stress worse for workers
Knowledge-focused Recruiting nowThis study looks at whether low oxygen levels (like at high altitudes) increase the risk of heat stress during moderate work in hot environments. Twenty healthy young and older men will walk on a treadmill in a hot room, once with normal oxygen and once with low oxygen. Researche…
Phase: NA • Sponsor: University of Ottawa • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study aims to understand severe breathing crises in kids with lung condition
Knowledge-focused Recruiting nowThis study compares severe respiratory infections in children with bronchopulmonary dysplasia (BPD) to those without BPD. Researchers will look back at past cases and follow new cases until 2030. The goal is to learn what makes these infections more dangerous for children with BP…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Breathing battle: which CPAP is best for tiny lungs?
Knowledge-focused Recruiting nowThis study compares two types of CPAP machines that help premature babies breathe. One delivers a constant flow of air, the other a variable flow. Researchers will measure the babies' diaphragm activity to see if constant flow works just as well. The study involves 20 infants bor…
Phase: NA • Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Lung cancer drug tislelizumab under Real-World scrutiny in 440-Patient european study
Knowledge-focused Recruiting nowThis study is tracking how the cancer drug tislelizumab is actually used in everyday European clinics for patients with advanced non-small cell or small cell lung cancer. Researchers will observe 440 participants to see treatment patterns, dosing changes, and real-world outcomes …
Sponsor: BeOne Medicines • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Timing of lung maneuver may reduce surgery complications
Knowledge-focused Recruiting nowThis study looks at when to perform a lung recruitment maneuver—a procedure that reopens collapsed lung areas—during robotic prostate surgery. Researchers will compare doing it before or after the patient is tilted head-down and gas is pumped into the abdomen. The goal is to see …
Phase: NA • Sponsor: Ankara University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Lung fluid may replace biopsies for cancer testing
Knowledge-focused Recruiting nowThis study looks at fluid from around the lungs (pleural effusion) in people with non-small cell lung cancer. Researchers want to see how often important cancer markers like PD-L1, ALK, and EGFR can be found in that fluid. They will also check if the amount of fluid tested affect…
Phase: NA • Sponsor: Naestved Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Frailty and muscle loss may predict outcomes in lung scarring patients
Knowledge-focused Recruiting nowThis study looks at 100 adults aged 65 and older with fibrosing interstitial lung disease, a condition that scars the lungs and shortens life. Researchers will assess frailty and muscle loss (sarcopenia) using questionnaires and tests to see if these factors predict hospital stay…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Extra oxygen boosts walking distance for lung patients?
Knowledge-focused Recruiting nowThis study looks at whether giving extra oxygen during a 6-minute walk test helps people with chronic lung disease walk farther and feel better. About 114 adults with conditions like COPD or interstitial lung disease will do two walking tests—one with their usual oxygen and one w…
Phase: NA • Sponsor: Istituti Clinici Scientifici Maugeri SpA • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Swiss study aims to curb antibiotic overuse with new guidelines
Knowledge-focused Recruiting nowThis study tests whether implementing new Swiss national guidelines for acute respiratory infections can reduce unnecessary antibiotic prescribing in primary care. Researchers will work with 200 family doctors in quality circles and walk-in clinics, providing training and materia…
Phase: NA • Sponsor: Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Scientists launch major study to unravel mysteries of rare lung infections
Knowledge-focused Recruiting nowThis study aims to learn more about non-tuberculous mycobacterial (NTM) infections, which cause repeated lung and other organ infections. Researchers will study up to 1,000 participants to understand the genetics, symptoms, and best treatments for these infections. The study also…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Scientists dive deep into the roots of a mysterious lung disease
Knowledge-focused Recruiting nowThis study aims to understand how lymphangioleiomyomatosis (LAM) damages the lungs at the cellular and genetic level. Researchers will follow up to 2,000 participants, including women with LAM and healthy volunteers, using advanced imaging and lab tests. The goal is to find the p…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Cancer samples sought to unlock treatment secrets
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Lung cancer umbrella study aims to match treatments to tumor type
Knowledge-focused Recruiting nowThis large study is testing many different drug combinations, including the immunotherapy pembrolizumab, in people with advanced non-small cell lung cancer. The goal is to see which treatments work best based on specific tumor features like PD-L1 levels and histology. Over 1,000 …
Sponsor: Merck Sharp & Dohme LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Could slower breathing on ventilators save lungs? small study aims to find out
Knowledge-focused Recruiting nowThis pilot study tests whether using a lower breathing rate on ventilators is safe and practical for critically ill patients. About 56 adults on breathing machines will be randomly assigned to either the new lower-rate approach or standard care. The goal is to see if the new meth…
Phase: NA • Sponsor: Reinier de Graaf Groep • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study aims to find best exercise test for lung disease patients
Knowledge-focused Recruiting nowThis observational study compares how people with bronchiectasis and healthy volunteers respond to different exercise tests, including a 6-minute stepper test, a 6-minute walk test, and a 1-minute sit-to-stand test. Researchers will measure breathing, heart rate, and muscle stren…
Sponsor: Hacettepe University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Massive russian study to map severe asthma treatment gaps
Knowledge-focused Recruiting nowThis study is observing 5,000 adults in Russia with severe, uncontrolled asthma who are not taking biologic medications. Researchers will collect information on their current treatments, health history, and lifestyle factors. The goal is to better understand how these patients ar…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Lung cancer DNA hunt: 800 patients join search for clues
Knowledge-focused Recruiting nowThis study is collecting tumor tissue and blood samples from 800 people with lung cancer to look for changes in a gene pathway called EGFR. The goal is to better understand the DNA mutations that drive the disease. No new treatment is being tested; instead, researchers hope to id…
Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Brazilian lung cancer study seeks to map Real-World treatment patterns
Knowledge-focused Recruiting nowThis study reviews medical records of 250 adults in Brazil with advanced non-squamous non-small cell lung cancer whose cancer progressed after platinum-based chemotherapy. Researchers will describe patient characteristics, treatments used, and outcomes in routine practice. The go…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Can couples coping together ease the burden of advanced cancer?
Knowledge-focused Recruiting nowThis study looks at whether a program called 'Couples Coping Together Against Cancer' is helpful and practical for people with advanced cancers like stage IV breast cancer, glioblastoma, or lung cancer, and their partners. Researchers at City of Hope will enroll 160 couples to se…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Can a smartwatch and virtual rehab keep COPD patients out of the hospital?
Knowledge-focused Recruiting nowThis study is testing whether a program that includes virtual pulmonary rehabilitation, integrated care, and remote monitoring using a smartwatch and home spirometer is feasible for people with COPD after a recent flare-up. Researchers will enroll 100 patients and track how many …
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
CF Drug's hidden impact on gut and lung bugs revealed
Knowledge-focused Recruiting nowThis study tracks 253 cystic fibrosis patients starting a new drug combination (elexacaftor/tezacaftor/ivacaftor). Researchers collect sputum, stool, and blood samples at the start, 6 months, and 1 year to see how the drug changes bacteria and inflammation in the lungs and gut. T…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists hunt for protein clues to Pneumonia's hidden causes
Knowledge-focused Recruiting nowThis study looks at proteins in lung fluid from 750 people with pneumonia to find biomarkers that could reveal what's causing the lung inflammation. Participants undergo a standard bronchoscopy with lung washings, plus a blood draw. The goal is to better understand different type…
Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study aims to detect lung damage earlier in young transplant patients
Knowledge-focused Recruiting nowThis study follows 2,000 children who receive stem cell transplants to better understand and detect lung injuries that can occur after the procedure. Researchers will track participants for two years, collecting samples and health data to find ways to diagnose problems earlier. T…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Your smartwatch could spot the flu before you feel it
Knowledge-focused Recruiting nowThis study enrolls healthy adults who are already part of a respiratory virus challenge study at the NIH. Participants wear a smartwatch and use a smartphone to track temperature, heart rate, coughs, and other health signals. The goal is to see if these devices can detect subtle …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
400 asthma patients tracked for 5 years to uncover environmental triggers
Knowledge-focused Recruiting nowThis study follows 400 adults aged 18–60 with moderate-to-severe asthma for up to 5 years. Researchers collect blood, urine, stool, dust, saliva, and lung samples at regular visits to see how bacteria and other environmental factors affect asthma symptoms and flare-ups. The goal …
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Asthma study aims to unlock personalized treatments for chinese patients
Knowledge-focused Recruiting nowThis observational study is enrolling 355 adults with asthma in China to describe their clinical features, treatment patterns, and biological markers. Researchers will analyze lung function, imaging, and blood biomarkers to identify distinct asthma subtypes. The goal is to gather…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Rare sinus cancer study aims to clarify treatment outcomes
Knowledge-focused Recruiting nowThis study follows people with a rare and advanced cancer of the nasal cavity and sinuses called T4 sinonasal adenoid cystic carcinoma. All participants receive the standard treatment: surgery followed by radiation therapy. The goal is to measure how long people live without the …
Sponsor: Eye & ENT Hospital of Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
HIV and oral cancer: what blocks access to care?
Knowledge-focused Recruiting nowThis study talks to people living with HIV from diverse backgrounds to learn what helps or hinders them from getting oral health care and cancer prevention. Researchers will hold focus groups and use questionnaires to understand barriers and gather ideas for improvement. The goal…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Heart valve study aims to predict who recovers best after surgery
Knowledge-focused Recruiting nowThis study at Mayo Clinic looks at how changes in the blood vessels of the lungs affect people with heart valve disease. Researchers will use echocardiograms during routine heart catheterization to measure these changes in 600 adults scheduled for valve procedures. The goal is to…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC